Intestinal Research

Original Articles

IBD

Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study: Hsu-Heng Yen, Meng-Tzu Weng, Chien-Chih Tung, Yu-Ting Wang, Yuan Ting Chang, Chin-Hao Chang, Ming-Jium Shieh, Jau-Min Wong, Shu-Chen Wei; Intest Res 2019;17(1):54-62. Published online November 20, 2018; DOI: https://doi.org/10.5217/ir.2018.00096

Background/Aims
Incidences of inflammatory bowel diseases (IBDs), ulcerative colitis (UC), and Crohn’s disease (CD), have been increasing in Asia. In this study, we report the relevant clinical characteristics and determined the epidemiological trend of IBD in Taiwan from 2001 to 2015.
Methods
A retrospective study was conducted to analyze data recorded from January 2001 through December 2015 in the registered database compiled by the National Health Insurance and provided by the Ministry of Health and Welfare, Taiwan.
Results
A total of 3,806 patients with catastrophic IBD illness were registered from 2001 to 2015 in Taiwan (CD, 919; UC, 2,887). The crude incidence of CD increased from 0.17/100,000 in 2001 to 0.47/100,000 in 2015, whereas that of UC increased from 0.54/100,000 in 2001 to 0.95/100,000 in 2015. The prevalence of CD increased from 0.6/100,000 in 2001 to 3.9/100,000 in 2015, whereas that of UC increased from 2.1/100,000 in 2001 to 12.8/100,000 in 2015. The male-to-female ratio in the study sample was 2.19 for CD and 1.62 for UC. The median age of those registered with CD was lower than that of those registered for UC: 38.86 and 44.86 years, respectively. A significantly greater increase in CD incidence rate was identified among 20 to 39-year-old compared with other age groups.
Conclusions
Using Taiwan’s nationwide insurance database, we determined that the number of patients with CD increased more rapidly during the study period than the number of patients with UC, especially among age 20 to 39-year-old, resulting in a decreased UC-to-CD ratio.

Citations

Citations to this article as recorded by

Attitudes to medication and effects of IBD nursing service among patients with inflammatory bowel disease in Taiwan
Chen‐Ta Yang, Tsui‐Chun Hsu, Yang‐Yuan Chen, Siou‐Ping Huang, Hsu‐Heng Yen
Advances in Digestive Medicine.2024; 11(3): 162. CrossRef
27-Hydroxycholesterol activates the GSK-3β/β-catenin signaling pathway resulting in intestinal fibrosis by inducing oxidative stress: effect of dietary interventions
Wei Xiao, Chunyan Hu, Yifan Ni, Jie Wang, Kailin Jiao, Ming Zhou, Zhong Li
Inflammation Research.2024; 73(2): 289. CrossRef
Unraveling the blood microbiome: novel insights into inflammasome responses in Crohn’s disease
Duygu Kirkik, Sevgi Kalkanli Tas, Alpaslan Tanoglu
European Journal of Gastroenterology & Hepatology.2024; 36(8): 975. CrossRef
Magnifying Endoscopy With Narrow Band Imaging for Graft Failure and Disease Recurrence in Patients With Crohn Disease After Intestinal Transplantation: 2 Case Reports
Chen-Huan Yu, Yun Chen, Chien-Chen Tsai, Tzong-Hsi Lee, Ya-Hui Tsai, Chen-Shuan Chung
Transplantation Proceedings.2024; 56(2): 422. CrossRef
Association between nonalcoholic fatty liver disease and incidence of inflammatory bowel disease: a nationwide population‑based cohort study
Ying-Hsiang Wang, Chi-Hsiang Chung, Tien-Yu Huang, Chao-Feng Chang, Chi-Wei Yang, Wu-Chien Chien, Yi-Chiao Cheng
Intestinal Research.2024;[Epub] CrossRef
Risk factors of mortality following hospital admission for Crohn's disease: A cohort study at a tertiary referral center in Taiwan
Po‐Han Huang, Wey‐Ran Lin, Puo‐Hsien Le, Cheng‐Yu Lin, Chun‐Wei Chen, Ren‐Chin Wu, Jun‐Te Hsu, Wen‐Sy Tsai, Ming‐Wei Lai, Sen‐Yung Hsieh, Ming‐Yao Su, Cheng‐Tang Chiu, Chia‐Jung Kuo
Advances in Digestive Medicine.2024; 11(2): 81. CrossRef
Exacerbated gastrointestinal symptoms and long COVID in IBD patients with SARS-CoV-2 infection: A multi-center study from taiwan
Tsung-Yu Tsai, Jia-Feng Wu, Meng-Tzu Weng, Chiao-Hsiung Chuang, Tien-Yu Huang, Wei-Chen Tai, Chi-Ming Tai, Chen-Shuan Chung, Chih-Cheng Chen, Ching-Pin Lin, Yuan-Yao Tsai, Shu-Chen Wei
Journal of the Formosan Medical Association.2024; 123(8): 866. CrossRef
Global Epidemiology and Geographic Variations of Pediatric-Onset Inflammatory Bowel Disease: A Comprehensive Analysis of the Global Burden of Disease Study 1990 to 2019
Yichen Wang, Chun-Wei Pan, Yuting Huang, Xin Zheng, Si Li, Mingyue He, Jana G Hashash, Francis A Farraye, Adam C Ehrlich
Inflammatory Bowel Diseases.2024;[Epub] CrossRef
Temporal Trends of Inflammatory Bowel Diseases in Taiwan from 2016 to 2020: A Population-Based Study
Chia-Jung Kuo, Cheng-Yu Lin, Puo-Hsien Le, Yao-Wei Kuo, Chen-Ming Hsu, Ming-Wei Lai, Wey-Ran Lin, Ming-Ling Chang, Ming-Yao Su, Cheng-Tang Chiu, Chee-Jen Chang
Digestive Diseases and Sciences.2024; 69(9): 3172. CrossRef
High prevalence of vitamin D deficiency in Taiwanese patients with inflammatory bowel disease
Chen-Ta Yang, Hsu-Heng Yen, Pei-Yuan Su, Yang-Yuan Chen, Siou-Ping Huang
Scientific Reports.2024;[Epub] CrossRef
Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Hsu-Heng Yen, Jia-Feng Wu, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin
Intestinal Research.2024; 22(3): 213. CrossRef
Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Jia-Feng Wu, Hsu-Heng Yen, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin
Intestinal Research.2024; 22(3): 250. CrossRef
Real‐world experience of adalimumab therapy for patients with ulcerative colitis: A single tertiary medical center experience in Central Taiwan
Hsu‐Heng Yen, Yu‐Chun Hsu, Chu‐Hsuan Kuo, Tsui‐Chun Hsu, Yang‐Yuan Chen
Advances in Digestive Medicine.2023; 10(1): 28. CrossRef
Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study
Wei-Chen Lin, Wei-Chen Tai, Chung-Hsin Chang, Chia-Hung Tu, I-Che Feng, Ming-Jium Shieh, Chen-Shuan Chung, Hsu-Heng Yen, Jen-Wei Chou, Jau-Min Wong, Yu-Hwa Liu, Tien-Yu Huang, Chiao-Hsiung Chuang, Tzung-Jiun Tsai, Feng-Fan Chiang, Chien-Yu Lu, Wen-Hung Hs
Inflammatory Bowel Diseases.2023; 29(11): 1730. CrossRef
Seronegative spondyloarthropathy-associated inflammatory bowel disease
Chrong-Reen Wang, Hung-Wen Tsai
World Journal of Gastroenterology.2023; 29(3): 450. CrossRef
Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome associated with inflammatory bowel disease: Report of four patients
Mingwei Ma, Yuchen Liu, Shengyan Liu, Chen Li
International Journal of Rheumatic Diseases.2023; 26(5): 996. CrossRef
Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
Clinical Endoscopy.2023; 56(2): 239. CrossRef
Serum amyloid protein A in inflammatory bowel disease: from bench to bedside
Rirong Chen, Qia Chen, Jieqi Zheng, Zhirong Zeng, Minhu Chen, Li Li, Shenghong Zhang
Cell Death Discovery.2023;[Epub] CrossRef
Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
Intestinal Research.2023; 21(3): 339. CrossRef
Diagnosis of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Han Hee Lee, Jae Jun Park, Bo-In Lee, Ida Hilmi, Jose Sollano, Zhi Hua Ran
Intestinal Research.2023; 21(3): 328. CrossRef
Risk of Attempted Suicide Among Patients with Inflammatory Bowel Disease: A Nationwide Longitudinal Follow-Up Study
Yen-Po Wang, Bing Zhang, Hohui E. Wang, Ya-Mei Bai, Shih-Jen Tsai, Tzeng-Ji Chen, Mu-Hong Chen
Diseases of the Colon & Rectum.2023;[Epub] CrossRef
Suboptimal Outcomes and Retreatment Rate of Patients With Crohn's Disease After Forced Discontinuation of Biologics: A Nationwide Population‐Based Study
Nai‐Yu Chen, Chiao‐Hsiung Chuang, Yu‐Ching Chang, Yea‐Huei Kao Yang, Peng‐Hsu Chen, Ching‐Lan Cheng
Clinical Pharmacology & Therapeutics.2023; 114(4): 914. CrossRef
Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission
Shun-Wen Hsiao, Ting-Chun Chen, Pei-Yuan Su, Chen-Ta Yang, Siou-Ping Huang, Yang-Yuan Chen, Hsu-Heng Yen
Diagnostics.2023; 13(20): 3268. CrossRef
The Prevalence and Risk Factors of Clostridioides difficile Infection in Inflammatory Bowel Disease: 10-Year South Korean Experience Based on the National Database
Eun Mi Song, Arum Choi, Sukil Kim, Sung Hoon Jung
Journal of Korean Medical Science.2023;[Epub] CrossRef
Increasing Prevalence and Stable Incidence Rates of Inflammatory Bowel Disease Among First Nations: Population-Based Evidence From a Western Canadian Province
Juan Nicolás Peña-Sánchez, Jessica Amankwah Osei, Jose Diego Marques Santos, Derek Jennings, Mustafa Andkhoie, Colten Brass, Germain Bukassa-Kazadi, Xinya Lu, Michelle Johnson-Jennings, Linda Porter, Rob Porter, Carol-Lynne Quintin, Rhonda Sanderson, Ulri
Inflammatory Bowel Diseases.2022; 28(4): 514. CrossRef
New‐onset Crohn's disease after interleukin‐17A inhibitor therapy with secukinumab: A report of an unusual case
Tung‐Lung Wu, Hui‐Ting Hsu, Hsu‐Heng Yen, Yang‐Yuan Chen
Advances in Digestive Medicine.2022; 9(3): 200. CrossRef
Impact of short-chain fatty acid supplementation on gut inflammation and microbiota composition in a murine colitis model
Jae Gon Lee, Jiyoung Lee, A-reum Lee, Su Vin Jo, Chan Hyuk Park, Dong Soo Han, Chang Soo Eun
The Journal of Nutritional Biochemistry.2022; 101: 108926. CrossRef
The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study
Chia-Jung Kuo, Puo-Hsien Le, Wei-Chen Tai, Keng-Liang Wu, Hsu-Heng Yen, Chih-Wei Yen, Shui-Yi Tung, Chen-Shuan Chung, Ming-Yao Su, Cheng-Tang Chiu
Journal of the Formosan Medical Association.2022; 121(9): 1689. CrossRef
Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang
Gut and Liver.2022; 16(1): 138. CrossRef
Shift to a Younger Age and Regional Differences in Inflammatory Bowel Disease in Korea: Using Healthcare Administrative Data
Seo-Hee Kim, Yujin Park, Seong Pyo Kim, Sung Hee Lee, Seak Hee Oh, Suk-Kyun Yang, Hyung-Jin Yoon, Kyung Mo Kim
Digestive Diseases and Sciences.2022; 67(11): 5079. CrossRef
Screening and Evaluation of Probiotics for Reducing Intestinal Inflammation
雅君陈
Hans Journal of Food and Nutrition Science.2022; 11(01): 44. CrossRef
Development and validation of a deep learning-based algorithm for colonoscopy quality assessment
Yuan-Yen Chang, Pai-Chi Li, Ruey-Feng Chang, Yu-Yao Chang, Siou-Ping Huang, Yang-Yuan Chen, Wen-Yen Chang, Hsu-Heng Yen
Surgical Endoscopy.2022; 36(9): 6446. CrossRef
Lycium barbarum Polysaccharides and Capsaicin Inhibit Oxidative Stress, Inflammatory Responses, and Pain Signaling in Rats with Dextran Sulfate Sodium-Induced Colitis
Yu-Shan Chen, Yu Zhi Lian, Wen-Chao Chen, Chun-Chao Chang, Alexey A. Tinkov, Anatoly V. Skalny, Jane C.-J. Chao
International Journal of Molecular Sciences.2022; 23(5): 2423. CrossRef
Schizophrenia and risk of new‐onset inflammatory bowel disease: a nationwide longitudinal study
Kuan‐Yi Sung, Bing Zhang, Hohui E. Wang, Ya‐Mei Bai, Shih‐Jen Tsai, Tung‐Ping Su, Tzeng‐Ji Chen, Ming‐Chih Hou, Ching‐Liang Lu, Yen‐Po Wang, Mu‐Hong Chen
Alimentary Pharmacology & Therapeutics.2022; 55(9): 1192. CrossRef
The Basic Concept of Claim Data-based Research
Su Bee Park, Jae Myung Cha
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2022; 22(1): 70. CrossRef
Changes in the Long-term Prognosis of Crohn’s Disease between 1986 and 2015: The Population-Based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study
Byong Duk Ye, Sung Noh Hong, Seung In Seo, Ye-Jee Kim, Jae Myung Cha, Kyoung Hoon Rhee, Hyuk Yoon, Young-Ho Kim, Kyung Ho Kim, Sun Yong Park, Seung Kyu Jeong, Ji Hyun Lee, Hyunju Park, Joo Sung Kim, Jong Pil Im, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim,
Gut and Liver.2022; 16(2): 216. CrossRef
Clinical characteristics and prognosis of amyotrophic lateral sclerosis with autoimmune diseases
Jin-Yue Li, Xiao-Han Sun, Dong-chao Shen, Xun-Zhe Yang, Ming-Sheng Liu, Li-Ying Cui, Weidong Le
PLOS ONE.2022; 17(4): e0266529. CrossRef
The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database
Gi Hyeon Seo, Sung Hoon Jung
Journal of Korean Medical Science.2022;[Epub] CrossRef
Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease
Meng-Tzu Weng, I-Lun Shih, Chien-Chih Tung, Yew-Loong Leong, Ming-Jium Shieh, Cheng-Yi Wang, Jau-Min Wong, Yen-Hsuan Ni, Shu-Chen Wei
Intestinal Research.2022; 20(2): 224. CrossRef
SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID
Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung
Intestinal Research.2022; 20(2): 171. CrossRef
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Sang Hyoung Park
Intestinal Research.2022; 20(2): 159. CrossRef
Effect of smoking on the development and outcomes of inflammatory bowel disease in Taiwan: a hospital-based cohort study
Bor-Cheng Chen, Meng-Tzu Weng, Chin-Hao Chang, Ling-Yun Huang, Shu-Chen Wei
Scientific Reports.2022;[Epub] CrossRef
Chronic bronchiectasis complicated with benign jejuno‐ileal pneumatosis intestinalis
Sheng‐Huan Wei, Li‐Ting Huang, Tang‐Hsiu Huang
Respirology Case Reports.2022;[Epub] CrossRef
Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia and in vitro Hepatic Lipogenic-Related Gene Expression: A Population-Based Cohort Study
Ni Tien, Tien-Yuan Wu, Cheng-Li Lin, Chia-Jui Wu, Chung-Y Hsu, Yi-Jen Fang, Yun-Ping Lim
Frontiers in Medicine.2022;[Epub] CrossRef
Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef
Trend and Geographic Variation in Incidence and Prevalence of Inflammatory Bowel Disease in Regions Across China: A Nationwide Employee Study Between 2013 and 2016
Hong Yang, Runing Zhou, Xiaoyin Bai, Mingyue Guo, Gechong Ruan, Li Wang, Jiaming Qian
Frontiers in Medicine.2022;[Epub] CrossRef
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Ki
Intestinal Research.2022; 20(3): 350. CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Lycium barbarum polysaccharides and capsaicin modulate inflammatory cytokines and colonic microbiota in colitis rats induced by dextran sulfate sodium
Yu Zhi Lian, Chun-Chao Chang, Yu-Shan Chen, Alexey A. Tinkov, Anatoly V. Skalny, Jane C.-J. Chao
Journal of Clinical Biochemistry and Nutrition.2022; 71(3): 229. CrossRef
Radiation Exposure among Patients with Inflammatory Bowel Disease: A Single-Medical-Center Retrospective Analysis in Taiwan
Chen-Ta Yang, Hsu-Heng Yen, Yang-Yuan Chen, Pei-Yuan Su, Siou-Ping Huang
Journal of Clinical Medicine.2022; 11(17): 5050. CrossRef
What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?
Su Bee Park, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2022; 16(5): 676. CrossRef
Dextran sodium sulfate alters antioxidant status in the gut affecting the survival of Drosophila melanogaster
Nishal Keshav, Ramyalakshmi Ammankallu, Shashidhar, Jagdish Gopal Paithankar, Manjeshwar Shrinath Baliga, Rajashekhar K. Patil, Avinash Kundadka Kudva, Shamprasad Varija Raghu
3 Biotech.2022;[Epub] CrossRef
Ethanol Extracts of Rice Bran and Whole Grain Adlay Seeds Mitigate Colonic Inflammation and Damage in Mice with Colitis
Hui-Chen Lo, Yu-Hsin Chen, Wen-Tzu Wu
Nutrients.2022; 14(18): 3877. CrossRef
Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intestinal Research.2022; 20(4): 418. CrossRef
Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease
Shun-Wen Hsiao, Hsu-Heng Yen, Yang-Yuan Chen
Gut and Liver.2022; 16(6): 840. CrossRef
Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study
Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Ge
Gut and Liver.2022; 16(6): 907. CrossRef
The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
Satimai Aniwan, Priscila Santiago, Edward V. Loftus, Sang Hyoung Park
United European Gastroenterology Journal.2022; 10(10): 1063. CrossRef
Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study
Bing Zhang, Hohui E Wang, Ya-Mei Bai, Shih-Jen Tsai, Tung-Ping Su, Tzeng-Ji Chen, Yen-Po Wang, Mu-Hong Chen
Gut.2021; 70(1): 85. CrossRef
The four epidemiological stages in the global evolution of inflammatory bowel disease
Gilaad G. Kaplan, Joseph W. Windsor
Nature Reviews Gastroenterology & Hepatology.2021; 18(1): 56. CrossRef
Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia
Shu-Chen Wei, Jose Sollano, Yee Tak Hui, Wei Yu, Paul V. Santos Estrella, Lyndon John Q. Llamado, Nana Koram
Expert Review of Gastroenterology & Hepatology.2021; 15(3): 275. CrossRef
Clinical outcomes and long‐term prognosis of perianal Crohn's disease in an Asian population
Eun Mi Song, Ho‐Su Lee, Ye‐Jee Kim, Eun Hye Oh, Nam Seok Ham, Jeongseok Kim, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang
Journal of Gastroenterology and Hepatology.2021; 36(6): 1571. CrossRef
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
Gut and Liver.2021; 15(1): 92. CrossRef
Incidence and Prevalence of Inflammatory Bowel Disease across Asia
Jihye Park, Jae Hee Cheon
Yonsei Medical Journal.2021; 62(2): 99. CrossRef
Clinical features and treatment of inflammatory bowel disease in a low-incidence area
Hsu-Heng Yen, Tsui-Chun Hsu, Mei-Wen Chen, Pei-Yuan Su, Yang-Yuan Chen
Medicine.2021; 100(10): e25090. CrossRef
The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study
Yi-Teng Hung, Puo-Hsien Le, Chia-Jung Kuo, Yu-Chuan Tang, Meng-Jiun Chiou, Cheng-Tang Chiu, Chang-Fu Kuo, Yu-Huei Huang
Journal of Clinical Medicine.2021; 10(6): 1311. CrossRef
Comparison of outcomes of cyclosporine A and infliximab for steroid‐refractory acute severe ulcerative colitis
Eun Mi Song, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Byong Duk Ye
Journal of Gastroenterology and Hepatology.2021; 36(9): 2463. CrossRef
The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: A modeling study
Meysam Olfatifar, Mohammad Reza Zali, Mohamad Amin Pourhoseingholi, Hedieh Balaii, Shaghayegh Baradaran Ghavami, Maria Ivanchuk, Pavlo Ivanchuk, Saeed hashemi Nazari, Shabnam shahrokh, Siamak Sabour, Soheila Khodakarim, Hamid Asadzadeh Aghdaei, Pejman Roh
BMC Gastroenterology.2021;[Epub] CrossRef
Enteroscopy in Crohn’s Disease: Are There Any Changes in Role or Outcomes Over Time? A KASID Multicenter Study
Seong Ran Jeon, Jin-Oh Kim, Jeong-Sik Byeon, Dong-Hoon Yang, Bong Min Ko, Hyeon Jeong Goong, Hyun Joo Jang, Soo Jung Park, Eun Ran Kim, Sung Noh Hong, Jong Pil Im, Seong-Eun Kim, Ja Seol Koo, Chang Soo Eun, Dong Kyung Chang
Gut and Liver.2021; 15(3): 375. CrossRef
Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
Hsu-Heng Yen, Pei-Yuan Su, Siou-Ping Huang, Lisha Wu, Tsui-Chun Hsu, Ya-Huei Zeng, Yang-Yuan Chen, Wan-Long Chuang
PLOS ONE.2021; 16(5): e0252286. CrossRef
Fecal microbiota profile in patients with inflammatory bowel disease in Taiwan
Tien-En Chang, Jiing-Chyuan Luo, Ueng-Cheng Yang, Yi-Hsiang Huang, Ming-Chih Hou, Fa-Yauh Lee
Journal of the Chinese Medical Association.2021; 84(6): 580. CrossRef
Risk of Inflammatory Bowel Disease Following Appendectomy in Adulthood
Wei-Sheng Chung, Sunny Chung, Chung-Y Hsu, Cheng-Li Lin
Frontiers in Medicine.2021;[Epub] CrossRef
Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management
Jihye Park, Sinyoung Park, Shin Ae Lee, Soo Jung Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2021; 36(5): 1040. CrossRef
Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis
Ho Min Yong, Sung-Jo Park, Seong Ran Jeon, Heesu Park, Hyun Gun Kim, Tae Hee Lee, Junseok Park, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Hyeon Jeong Goong, Suyeon Park
Medicine.2021; 100(34): e27065. CrossRef
SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID
Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung
The Korean Journal of Gastroenterology.2021; 78(2): 117. CrossRef
Lentinan-Based Oral Nanoparticle Loaded Budesonide With Macrophage-Targeting Ability for Treatment of Ulcerative Colitis
Meisi Lin, Lingling Dong, Qiyan Chen, Haiting Xu, Xiaoqin Han, Ruifeng Luo, Xiulan Pu, Shanshan Qi, Wenbiao Nie, Meilin Ma, Yitao Wang, Fei Gao, Jinming Zhang
Frontiers in Bioengineering and Biotechnology.2021;[Epub] CrossRef
Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study
Hee Seung Hong, Kyuwon Kim, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef
Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef
Epidemiology and diagnosis of inflammatory bowel diseases
Kang-Moon Lee
Journal of the Korean Medical Association.2021; 64(9): 579. CrossRef
Current status of inflammatory bowel diseases in Korea
Suk-Kyun Yang
Journal of the Korean Medical Association.2021; 64(9): 572. CrossRef
Is the Long-term Disease Course of Elderly-Onset Ulcerative Colitis Different from That of Non-Elderly-Onset Ulcerative Colitis?
Jin Wook Lee, Eun Soo Kim
Gut and Liver.2021; 15(5): 639. CrossRef
Association Between Ischemic Optic Neuropathy and Inflammatory Bowel Disease: A Population-Based Cohort Study in Taiwan
Ting-Yi Lin, Yi-Fen Lai, Po-Huang Chen, Chi-Hsiang Chung, Ching-Long Chen, Yi-Hao Chen, Jiann-Torng Chen, Po-Chen Kuo, Wu-Chien Chien, Yun-Hsiu Hsieh
Frontiers in Medicine.2021;[Epub] CrossRef
Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park
BMC Gastroenterology.2021;[Epub] CrossRef
Exploring Links Between Industrialization, Urbanization, and Chinese Inflammatory Bowel Disease
Guanglin Cui, Hanzhe Liu, Gang Xu, Jann-Birger Laugsand, Zhigang Pang
Frontiers in Medicine.2021;[Epub] CrossRef
Endoscopic Mucosal Healing as a Treatment Target in Ulcerative Colitis: Does It Have the Same Role in Asian Patients?
Suk-Kyun Yang, Sang Hyoung Park, Byong Duk Ye
Gut and Liver.2021; 15(6): 942. CrossRef
Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom?
Soo-Young Na, Yun-Jeong Lim
Diagnostics.2021; 11(12): 2240. CrossRef
Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
Digestive Diseases and Sciences.2020; 65(5): 1436. CrossRef
Crohn’s disease and ulcerative colitis are associated with different lipid profile disorders: a nationwide population‐based study
Hosim Soh, Jong Pil Im, Kyungdo Han, Seona Park, Seung Wook Hong, Jeong Min Moon, Eun Ae Kang, Jaeyoung Chun, Hyun Jung Lee, Joo Sung Kim
Alimentary Pharmacology & Therapeutics.2020; 51(4): 446. CrossRef
The epidemiology of inflammatory bowel disease: East meets west
Wing Yan Mak, Mirabella Zhao, Siew Chien Ng, Johan Burisch
Journal of Gastroenterology and Hepatology.2020; 35(3): 380. CrossRef
Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
Minkyung Han, Yoon Suk Jung, Jae Hee Cheon, Sohee Park
Yonsei Medical Journal.2020; 61(1): 48. CrossRef
A case with cytomegalovirus colitis and toxic megacolon initially diagnosed as Crohn's disease
Shan-Han Chang, Hsin-Yun Sun, Chia-Tung Shun, Shu-Chen Wei
Journal of the Formosan Medical Association.2020; 119(9): 1442. CrossRef
Trends in Healthcare Costs for Inflammatory Bowel Disease in South Korea
Yoon Suk Jung
Gut and Liver.2020; 14(1): 3. CrossRef
Cost‐effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease
Joyce H S You, Xinchan Jiang, Wally H Lee, Paul K S Chan, Siew C Ng
Journal of Gastroenterology and Hepatology.2020; 35(9): 1515. CrossRef
Crohn’s disease
Giulia Roda, Siew Chien Ng, Paulo Gustavo Kotze, Marjorie Argollo, Remo Panaccione, Antonino Spinelli, Arthur Kaser, Laurent Peyrin-Biroulet, Silvio Danese
Nature Reviews Disease Primers.2020;[Epub] CrossRef
Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products
Karma Yeshi, Roland Ruscher, Luke Hunter, Norelle L. Daly, Alex Loukas, Phurpa Wangchuk
Journal of Clinical Medicine.2020; 9(5): 1273. CrossRef
Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis
Hsu-Heng Yen, Mei-Wen Chen, Yu-Yao Chang, Hsuan-Yuan Huang, Tsui-Chun Hsu, Yang-Yuan Chen
PeerJ.2020; 8: e9537. CrossRef
Association between inflammatory bowel disease and bullous pemphigoid: a population-based case–control study
Yi-Ju Chen, Chao-Kuei Juan, Yun-Ting Chang, Chun-Ying Wu, Hsiu J. Ho, Hsiao-Ching Tseng
Scientific Reports.2020;[Epub] CrossRef
Lactobacilli and bifidobacteria derived from infant intestines may activate macrophages and lead to different IL-10 secretion
Huijing Liang, Zihao Luo, Zhonghua Miao, Xi Shen, Ming Li, Xuguang Zhang, Jiehua Chen, Xiaolei Ze, Qiwei Chen, Fang He
Bioscience, Biotechnology, and Biochemistry.2020; 84(12): 2558. CrossRef
Temporal trend of disease recognition, treatment paradigm, and clinical outcomes of Crohn disease in Thailand from 2000 through 2017
Julajak Limsrivilai, Satimai Aniwan, Asawin Sudcharoen, Natapat Chaisidhivej, Piyaphan Prueksapanich, Nonthalee Pausawasdi, Phunchai Charatcharoenwitthaya, Supot Pongprasobchai, Sathaporn Manassatit
Medicine.2020; 99(38): e22216. CrossRef
Combination of Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis Shows a Stronger Anti-Inflammatory Effect than Individual Strains in HT-29 Cells
Sing-Chung Li, Wei-Fang Hsu, Jung-Su Chang, Chun-Kuang Shih
Nutrients.2019; 11(5): 969. CrossRef
Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study
Hsin-Hua Chen, Wen-Cheng Chao, Yi-Hsing Chen, Tsu-Yi Hsieh, Kuo-Lung Lai, Yi-Ming Chen, Wei-Ting Hung, Ching-Tsai Lin, Chih-Wei Tseng, Ching-Heng Lin
Arthritis Research & Therapy.2019;[Epub] CrossRef
Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease
Youn I Choi, Tae Jun Kim, Dong Kyun Park, Jun-won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim
International Journal of Colorectal Disease.2019; 34(10): 1713. CrossRef
Microscopic features of small bowel mucosa of patients with Crohn’s disease
Yun Cui, Shi-yuan Lu, Jie Xu, Yan-shen Peng, Qi Miao, Xiao-qing Wang, Xiao-yu Chen, Zhi-hua Ran
BMC Gastroenterology.2019;[Epub] CrossRef

11,992 View
510 Download
106 Web of Science
102 Crossref

Colorectal neoplasia

Rates of metachronous adenoma after curative resection for left-sided or right-sided colon cancer: Yuk Fai Lam, Wai Kay Seto, Teresa Tong, Ka Shing Cheung, Oswens Lo, Ivan FN Hung, Wai Lun Law, Wai K Leung; Intest Res 2018;16(4):619-627. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00013

Abstract PDF PubReader ePub

Background/Aims
We determined the rates of metachronous colorectal neoplasm in colorectal cancer (CRC) patients after resection for right (R)-sided or left (L)-sided cancer.
Methods
Consecutive CRC patients who had undergone surgical resection for curative intent in our hospital between 2001 and 2004 were identified. R-sided colonic cancers refer to cancer proximal to splenic flexure whereas L-sided cancers include rectal cancers. Patients were included only if they had a clearing colonoscopy performed either before or within 6 months after the operation. Findings of surveillance colonoscopy performed up to 5 years after colonic resection were included in the analysis.
Results
Eight hundred and sixty-three CRC patients underwent curative surgical resection during the study period. Three hundred and twenty-seven patients (107 R-sided and 220 L-sided) fulfilled the inclusion criteria and had at least 1 postoperative surveillance colonoscopy performed. The proportion of patients who had polyp and adenoma on surveillance colonoscopy was significantly higher among patients with L-sided than R-sided cancers (polyps: 30.9% vs. 19.6%, P=0.03; adenomas: 25.5% vs. 13.1%, P=0.01). The mean number of adenoma per patient on surveillance colonoscopy was also higher for patients with L-sided than R-sided tumors (0.52; 95% confidence interval [CI], 0.37–0.68 vs. 0.22; 95% CI, 0.08–0.35; P<0.01). Multivariate analysis showed that L-sided cancers, age, male gender and longer follow-up were independent predictors of adenoma detection on surveillance colonoscopy.
Conclusions
Patients with Lsided cancer had a higher rate of metachronous polyps and adenoma than those with R-sided cancer on surveillance colonoscopy.

Citations

Citations to this article as recorded by

The absolute number of small and diminutive adenomas with high-grade dysplasia is substantially higher compared with large adenomas: a retrospective pooled study
Jiancheng Zhang, Huajun Sun, Fei Xiong, Shan Lei, Guanyu Zhou, Xun Xiao, Lin Liu, Pu Wang
Frontiers in Oncology.2024;[Epub] CrossRef
A survey of current practices in post-polypectomy surveillance in Korea
Jeongseok Kim, Tae-Geun Gweon, Min Seob Kwak, Su Young Kim, Seong Jung Kim, Hyun Gun Kim, Eun Ran Kim, Sung Noh Hong, Eun Sun Kim, Chang Mo Moon, Dae Seong Myung, Dong Hoon Baek, Shin Ju Oh, Hyun Jung Lee, Ji Young Lee, Yunho Jung, Jaeyoung Chun, Dong-Hoo
Intestinal Research.2024; 22(2): 186. CrossRef
Delineation of gastrointestinal tumors biopsies using a fluorescence lifetime imaging optical fiber probe
D. Suraci, E. Baria, L. Tirloni, J. L. Lagarto, S. Buccianti, C. Agostini, S. Pillozzi, L. Antonuzzo, A. Taddei, R. Cicchi
Journal of Biophotonics.2024;[Epub] CrossRef
IMMUNOREACT 9 metachronous rectal cancers have high HLA-ABC expression on healthy epithelium but a lower infiltration of CD3+ T cells than primary lesions
Beatrice Salmaso, Melania Scarpa, Valerio Pellegrini, Astghik Stepanyan, Roberta Salmaso, Andromachi Kotsafti, Federico Scognamiglio, Dario Gregori, Giorgio Rivella, Ottavia De Simoni, Giulia Becherucci, Silvia Negro, Chiara Vignotto, Gaya Spolverato, Ces
Scientific Reports.2024;[Epub] CrossRef
Risk factors of advanced metachronous neoplasms in surveillance after colon cancer resection
Kwangwoo Nam, Jeong Eun Shin
The Korean Journal of Internal Medicine.2021; 36(2): 305. CrossRef

6,921 View
117 Download
4 Web of Science
5 Crossref

IBD

Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease: Shinichiro Shinzaki, Toshimitsu Fujii, Shigeki Bamba, Maiko Ogawa, Taku Kobayashi, Masahide Oshita, Hiroki Tanaka, Keiji Ozeki, Sakuma Takahashi, Hiroki Kitamoto, Kazuhito Kani, Sohachi Nanjo, Takeshi Sugaya, Yuko Sakakibara, Toshihiro Inokuchi, Kazuki Kakimoto, Akihiro Yamada, Hisae Yasuhara, Yoko Yokoyama, Takuya Yoshino, Akira Matsui, Misaki Nakamura, Taku Tomizawa, Ryosuke Sakemi, Noriko Kamata, Toshifumi Hibi; Intest Res 2018;16(4):609-618. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00044

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate the safety of H. pylori eradication therapy for IBD patients.
Methods
IBD patients with H. pylori eradication from 2005 to 2015 (eradication group) and control patients (non-eradication group; 2 paired IBD patients without H. pylori eradication matched with each eradicated patient) were included. IBD exacerbation (increased/additional IBD drug or IBD-associated hospitalization/surgery) and disease improvement based on the physicians’ global assessment were investigated at baseline, and at 2 and 6 months after eradication or observation.
Results
A total of 429 IBD (378 ulcerative colitis, 51 Crohn’s disease) patients, comprising 144 patients in the eradication group and 285 patients in the non-eradication group, were enrolled at 25 institutions. IBD exacerbation was comparable between groups (eradication group: 8.3% at 2 months [odds ratio, 1.76; 95% confidence interval, 0.78–3.92; P=0.170], 11.8% at 6 months [odds ratio, 1.60; 95% confidence interval, 0.81–3.11; P=0.172]). Based on the physicians’ global assessment at 2 months, none of the patients in the eradication group improved, whereas 3.2% of the patients in the non-eradication group improved (P=0.019). Multivariate analysis revealed that active disease at baseline, but not H. pylori eradication, was an independent factor for IBD exacerbation during 2 months’ observation period. The overall eradication rate was 84.0%–comparable to previous reports in non-IBD patients.
Conclusions
H. pylori eradication therapy does not alter the short-term disease activity of IBD.

Citations

Citations to this article as recorded by

Factors Associated With Decision to Treat or Not to Treat Helicobacter pylori Infection in Children: Data From the EuroPedHp Registry
Thu Giang Le Thi, Katharina Werkstetter, Kallirroi Kotilea, Patrick Bontems, José Cabral, Maria Luz Cilleruelo, Michal Kori, Josefa Barrio, Matjaž Homan, Nicolas Kalach, Rosa Lima, Marta Tavares, Pedro Urruzuno, Zrinjka Misak, Vaidotas Urbonas, Sibylle Ko
Helicobacter.2024;[Epub] CrossRef
Impact of Helicobacter pylori Eradication on Inflammatory Bowel Disease Onset and Disease Activity: To Eradicate or Not to Eradicate?
Antonietta Gerarda Gravina, Raffaele Pellegrino, Veronica Iascone, Giovanna Palladino, Alessandro Federico, Rocco Maurizio Zagari
Diseases.2024; 12(8): 179. CrossRef
Bibliometric analysis of the correlation between H. pylori and inflammatory bowel disease
Yantong Li, Limin Li, Wenmeng Yin, Juyi Wan, Xiaolin Zhong
JGH Open.2024;[Epub] CrossRef
Discussion on the common controversies of Helicobacter pylori infection
Hang Yang, Yi Mou, Bing Hu
Helicobacter.2023;[Epub] CrossRef
Helicobacter pylori and Inflammatory Bowel Disease: An Unresolved Enigma
Juris Pokrotnieks, Stanislav Sitkin
Inflammatory Bowel Diseases.2023; 29(3): e5. CrossRef
Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems
Li Wang, Zheng-Min Cao, Li-Li Zhang, Xin-can Dai, Zhen-ju Liu, Yi-xian Zeng, Xin-Ye Li, Qing-Juan Wu, Wen-liang Lv
Frontiers in Immunology.2022;[Epub] CrossRef
Helicobacter pylori infection in patients with inflammatory bowel diseases: a single-centre, prospective, observational study in Egypt
Ekram W. Abd El-Wahab, Ebtessam I. Youssef, Ehab Hassouna
BMJ Open.2022; 12(5): e057214. CrossRef
Is the Presence of Helicobacter Pylori in the Colonic Mucosa, Provocative of Activity in Ulcerative Colitis?
Javad Ranjbar, Bita Geramizadeh, Kamran Bagheri Lankarani, Zahra Jowkar, Mitra Mirzai, Elham Moazamian
Clinical Pathology.2022;[Epub] CrossRef
Helicobacter pylori infection and inflammatory bowel diseases
Yu. P. Uspenskiy, N. V. Baryshnikova, A. N. Suvorov, A. V. Svarval
Russian Journal of Infection and Immunity.2021; 11(1): 68. CrossRef
Ulcerative colitis relapse after Helicobacter pylori eradication in a 12-year-old boy with duodenal ulcer
Yuji Fujita, Keiichi Tominaga, Takanao Tanaka, Takeshi Sugaya, Shigemi Yoshihara
BMC Gastroenterology.2021;[Epub] CrossRef
Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with Helicobacter pylori infection and co-existing inflammatory bowel disease
Hussam Murad, Misbahuddin Rafeeq, Mahmoud Mosli, Mamdouh Gari, Mohammed Basheikh
Journal of International Medical Research.2021;[Epub] CrossRef
Extra-Gastric Manifestations of Helicobacter pylori Infection
Antonietta G. Gravina, Kateryna Priadko, Paola Ciamarra, Lucia Granata, Angela Facchiano, Agnese Miranda, Marcello Dallio, Alessandro Federico, Marco Romano
Journal of Clinical Medicine.2020; 9(12): 3887. CrossRef
Comparison of new and classical point mutations associated with clarithromycin resistance in Helicobacter pylori strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance
Bekir Kocazeybek, Merve Kutlu Sakli, Pelin Yuksel, Mehmet Demirci, Reyhan Caliskan, Tevhide Ziver Sarp, Suat Saribas, Suleyman Demiryas, Fatma Kalayci, Huseyin Cakan, Hayriye Kirkoyun Uysal, Nesrin Gareayaghi, Sevgi Ergin, Yusuf Ziya Erzin, Kadir Bal, İhs
Journal of Medical Microbiology .2019; 68(4): 566. CrossRef
Review:Helicobacter pyloriand extragastric diseases
Francesco Franceschi, Marcello Covino, Claire Roubaud Baudron
Helicobacter.2019;[Epub] CrossRef

7,972 View
148 Download
15 Web of Science
14 Crossref

IBD

Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea: Ji Young Chang, Sung-Ae Jung, Chang Mo Moon, Seong-Eun Kim, Hye-Kyung Jung, Ki-Nam Shim; Intest Res 2018;16(4):599-608. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00012

Abstract PDF PubReader ePub

Background/Aims
Testing for hepatitis B virus (HBV) serologic markers and appropriate vaccination are required in the management of inflammatory bowel disease (IBD) patients. We evaluated immunogenicity for HBV in IBD patients and the response to the HBV vaccination.
Methods
From May 2014 to August 2016, patients diagnosed with IBD were prospectively included and evaluated for anti-HBs antibody, anti-HBc antibody, and HBs antigen. Among the 73 patients who were confirmed with nonimmunity to HBV, 44 patients who had completed the 3-dose HBV vaccination series received a single booster vaccination, while 29 patients who had not completed the vaccinations series or were unsure of receiving the vaccination received a full vaccination series.
Results
An optimal response was obtained in 70.5% of the patients in the booster group, and 89.7% of the patients in the full vaccination group. Age younger than 26 years (odds ratio [OR], 6.01; 95% confidence interval [CI], 1.15–31.32; P=0.033) and a complete previous vaccination series (OR, 0.15; 95% CI, 0.03–0.80; P=0.026) were associated with optimal vaccine response. Previous complete vaccination series (OR, 0.11; 95% CI, 0.02–0.73; P=0.022) was the only predictive factor for lower compliance.
Conclusions
The response to the HBV vaccination was lower in patients older than 26 years and for those patients with a complete vaccination history. Since patients with a complete vaccination history also had poor compliance, serum HBV-titers should be checked more thoroughly, and a full vaccination series should be administered in cases when there is a negative response to the booster vaccination.

Citations

Citations to this article as recorded by

Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study
Mohammad Shehab, Fatema Alrashed, Munerah Alyaseen, Zainab Safar, Tunrayo Adekunle, Ahmad Alfadhli, Talat Bessissow
Vaccines.2024; 12(4): 364. CrossRef
Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease
Anupam Kumar Singh, Anuraag Jena, Gaurav Mahajan, Ritin Mohindra, Vikas Suri, Vishal Sharma
Alimentary Pharmacology & Therapeutics.2022; 55(8): 908. CrossRef
Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study
Anurag Mishra, Amarender Singh Puri, Sanjeev Sachdeva, Ashok Dalal
Intestinal Research.2022; 20(4): 445. CrossRef
A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency
Elda Righi, Tolinda Gallo, Anna Maria Azzini, Fulvia Mazzaferri, Maddalena Cordioli, Mara Merighi, Evelina Tacconelli
Infectious Diseases and Therapy.2021; 10(2): 637. CrossRef
Vaccination in the Elderly and IBD
Anthony J. Choi, Preston Atteberry, Dana J. Lukin
Current Treatment Options in Gastroenterology.2019; 17(4): 492. CrossRef

7,863 View
142 Download
4 Web of Science
5 Crossref

IBD

High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India: Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja; Intest Res 2018;16(4):588-598. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00023

Abstract PDF PubReader ePub

Background/Aims
The data on the risk of tuberculosis (TB) reactivation with infliximab (IFX) in patients with inflammatory bowel disease (IBD) from TB endemic countries, like India, is limited. The risk of TB reactivation on IFX and its predictors in patients with IBD was assessed.
Methods
This retrospective review included consecutive patients with IBD who received IFX, and were on follow-up from January 2005 to November 2017. The data was recorded on age/disease duration, indications for IFX, screening for latent tuberculosis (LTB) before IFX, response to IFX, incidence and duration when TB developed after IFX, and type of TB (pulmonary [PTB]/extra-pulmonary [EPTB]/disseminated).
Results
Of 69 patients (22 ulcerative colitis/47 Crohn’s disease; mean age, 35.6±14.5 years; 50.7% males; median follow-up duration after IFX, 19 months [interquartile range, 5.5–48.7 months]), primary non-response at 8 weeks and secondary loss of response at 26 and 52 weeks were seen in 14.5%, 6% and 15% patients respectively. Prior to IFX, all patients were screened for LTB, 8 (11.6%) developed active TB (disseminated, 62.5%; EPTB, 25%; PTB, 12.5%) after a median of 19 weeks (interquartile range, 14.0–84.5 weeks) of IFX. Of these 8 patients’ none had LTB, even when 7 of 8 were additionally screened with contrast-enhanced chest tomography. Though not statistically significant, more patients with Crohn’s disease than ulcerative colitis (14.9% vs. 4.5%, P=0.21), and those with past history of TB (25% vs. 9.8%, P=0.21), developed TB. Age, gender, disease duration, or extraintestinal manifestations could not predict TB reactivation.
Conclusions
There is an extremely high rate of TB with IFX in Indian patients with IBD. Current screening techniques are ineffective and it is difficult to predict TB after IFX.

Citations

Citations to this article as recorded by

Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening
Suprabhat Giri, Sukanya Bhrugumalla, Akash Shukla, Sagar Gangadhar, Srujan Reddy, Sumaswi Angadi, Leela Shinde, Aditya Kale
Arab Journal of Gastroenterology.2024;[Epub] CrossRef
Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future
Manish Manrai, Atul Abhishek Jha, Saurabh Dawra, Aditya Vikram Pachisia
Future Pharmacology.2024; 4(1): 279. CrossRef
RATE OF INFECTION (TUBERCULOSIS) IN BRAZILIANS IBD PRIVATE PATIENTS: FOLLOW-UP 15 YEARS
Didia B CURY, Liana C B CURY, Ana C MICHELETTI, Rogério A OLIVEIRA, José J S GONÇALVES
Arquivos de Gastroenterologia.2024;[Epub] CrossRef
(Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review
Thomas Theo Brehm, Maja Reimann, Niklas Köhler, Christoph Lange
Clinical Microbiology and Infection.2024; 30(8): 989. CrossRef
“Mitigating tuberculosis reactivation risk in IBD patients on anti-TNF therapy”
Peeyush Kumar, Saurabh Kedia, Vineet Ahuja
Arab Journal of Gastroenterology.2024; 25(4): 455. CrossRef
Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review
Nina Jahnich, Peter D. Arkwright
Frontiers in Pharmacology.2023;[Epub] CrossRef
Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
Clinical Endoscopy.2023; 56(2): 239. CrossRef
CT in the detection of latent tuberculosis: a systematic review
N. Moore, M. Maher, G. Murphy, M. O'Callaghan Maher, O.J. O'Connor, M.F. McEntee
Clinical Radiology.2023; 78(8): 568. CrossRef
Miliary Tuberculosis in a Patient With Ulcerative Colitis Treated With Tofacitinib
Shruti Verma, Arshdeep Singh, Chandan Kakkar, Ashish Tripathi, Vandana Midha, Ajit Sood
ACG Case Reports Journal.2023; 10(6): e01066. CrossRef
The Risk of Opportunistic Infections in Patients with Inflammatory Bowel Disease
Maede Ghanaeipour, Nima Behnaminia, Erfan Khadem, Amirhossein Nafari
The International Journal of Gastroenterology and Hepatology Diseases.2022;[Epub] CrossRef
Association of Tumor Necrosis Factor α Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010–2017
Shereen S Katrak, Rongxia Li, Sue Reynolds, Suzanne M Marks, Jessica R Probst, Terence Chorba, Kevin Winthrop, Kenneth G Castro, Neela D Goswami
Open Forum Infectious Diseases.2022;[Epub] CrossRef
Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region
Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit
Alimentary Pharmacology & Therapeutics.2022; 55(11): 1431. CrossRef
Increased Risk of Infection With High Infliximab Trough Level
Suprabhat Giri, Harish Darak
Journal of Clinical Gastroenterology.2022; 56(4): 374. CrossRef
Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti‐TNF‐therapy—authors' reply
Peeyush Kumar, Sudheer Kumar Vuyyuru, Saurabh Kedia, Vineet Ahuja
Alimentary Pharmacology & Therapeutics.2022; 55(10): 1348. CrossRef
Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective
Shubhra Mishra, Anuraag Jena, Rinkalben Kakadiya, Vishal Sharma, Vineet Ahuja
Expert Review of Gastroenterology & Hepatology.2022; 16(8): 737. CrossRef
Tumor necrosis factor-alpha antibody labeled-polyethylene glycol-coated nanoparticles: A mesenchymal stem cells-based drug delivery system in the rat model of cisplatin-induced nephrotoxicity
Faten A. M. Abo-Aziza, Saleh M. Albarrak, Abdel-Kader A. Zaki, Shaymaa E. El-Shafey
Veterinary World.2022; : 2475. CrossRef
Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Saurabh Kedia, Pabitra Sahu, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Kumar, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Govind Makharia, Vineet Ahuja
Indian Journal of Gastroenterology.2022; 41(5): 446. CrossRef
Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia
Shu-Chen Wei, Jose Sollano, Yee Tak Hui, Wei Yu, Paul V. Santos Estrella, Lyndon John Q. Llamado, Nana Koram
Expert Review of Gastroenterology & Hepatology.2021; 15(3): 275. CrossRef
Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents
Adam Krusiński, Anna Grzywa-Celińska, Katarzyna Szewczyk, Luiza Grzycka-Kowalczyk, Justyna Emeryk-Maksymiuk, Janusz Milanowski, Andrew S. Day
International Journal of Inflammation.2021; 2021: 1. CrossRef
Long‐term outcomes of anti‐tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease
Sudheer K Vuyyuru, Devendra Desai, Saurabh Kedia, Pavan Dhoble, Pabitra Sahu, Bhaskar Kante, Samagra Agarwal, Sawan Bopanna, Rajan Dhingra, Pratap Mouli Venigalla, Raju Sharma, Siddhartha Datta Gupta, Govind Makharia, Peush Sahni, Vineet Ahuja
JGH Open.2021; 5(4): 420. CrossRef
Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
Sanchit Sharma, Arti Gupta, Saurabh Kedia, Samagra Agarwal, Namrata Singh, Sandeep Goyal, Saransh Jain, Vipin Gupta, Pabitra Sahu, Sudheer Kumar Vuyyuru, Bhaskar Kante, Raju Sharma, Rajesh Panwar, Peush Sahni, Govind Makharia, Vineet Ahuja
Intestinal Research.2021; 19(3): 291. CrossRef
Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease
Qin Yu Yang, Yi Juan Liu, Ye Xu, Lin Zhang, Cheng Dang Wang
Journal of Digestive Diseases.2021; 22(8): 473. CrossRef
COVID-19-associated opportunistic infections: a snapshot on the current reports
Amir Abdoli, Shahab Falahi, Azra Kenarkoohi
Clinical and Experimental Medicine.2021; 22(3): 327. CrossRef
Efficacy and Safety of Fecal Transplantation Versus Targeted Therapies in Ulcerative Colitis: Network Meta-Analysis
Sudheer K Vuyyuru, Saurabh Kedia, Mani Kalaivani, Pabitra Sahu, Bhaskar Kante, Peeyush Kumar, Mukesh K Ranjan, Govind Makharia, Ashwin Ananthakrishnan, Vineet Ahuja
Future Microbiology.2021; 16(15): 1215. CrossRef
A case report of probable ocular tuberculosis following biologics
Sudha K. Ganesh, Divya Thatikonda
Indian Journal of Ophthalmology - Case Reports.2021; 1(4): 683. CrossRef
Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park
BMC Gastroenterology.2021;[Epub] CrossRef
Tacrolimus as rescue therapy for steroid-dependent/steroid-refractory ulcerative colitis: Experience from tertiary referral center in India
Sukrit Sud, Sanjeev Sachdeva, Amarender Singh Puri
Indian Journal of Gastroenterology.2021; 40(6): 598. CrossRef
Vedolizumab in Inflammatory Bowel Disease: West versus East
Prasanta Debnath, Pravin M. Rathi
Inflammatory Intestinal Diseases.2021; 6(1): 1. CrossRef
Antitubercular Therapy Given to Differentiate Crohn’s Disease From Intestinal Tuberculosis Predisposes to Stricture Formation
Akshita Gupta, Venigalla Pratap Mouli, Srikant Mohta, Bhaskar Kante, Mani Kalaivani, Deepak Madhu, Pabitra Sahu, Sudheer Kumar, Raju Sharma, Peush Sahni, Prasenjit Das, Siddharth Datta Gupta, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Journal of Crohn's and Colitis.2020; 14(11): 1611. CrossRef
Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India
Pabitra Sahu, Sudheer K. Vuyyuru, Bhaskar Kante, Ashish Agarwal, Raju Sharma, Prasenjit Das, Rajesh Panwar, Saransh Jain, Sawan Bopanna, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Indian Journal of Gastroenterology.2020; 39(4): 388. CrossRef
Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model
Jung Min Kim, Da Hye Kim, Hyo Jeong Park, Hyun Woo Ma, I Seul Park, Mijeong Son, So Youn Ro, Seokmann Hong, Hyo Kyung Han, Soo Jeong Lim, Seung Won Kim, Jae Hee Cheon
Journal of Nanobiotechnology.2020;[Epub] CrossRef
Long-term outcomes in perianal fistulizing Crohn’s disease in a resource-limited setting: A cohort analysis
Sudheer K. Vuyyuru, Pabitra Sahu, Saurabh Kedia, Bhaskar Kante, Peeyush Kumar, Mukesh Kumar Ranjan, Raju Sharma, Govind Makharia, S. D. Gupta, Peush Sahni, Vineet Ahuja
Indian Journal of Gastroenterology.2020; 39(5): 435. CrossRef
Higher risk of tuberculosis in combination therapy for inflammatory bowel disease
Seong Ji Choi, Min Sun Kim, Eun Sun Kim, Juneyoung Lee, Jae Min Lee, Hyuk Soon Choi, Bora Keum, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang Duck Kim
Medicine.2020; 99(44): e22897. CrossRef
Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia
Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng
The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076. CrossRef
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
Nagesh Kamat, Saurabh Kedia, Uday C. Ghoshal, Abhimanyu Nehra, Govind Makharia, Ajit Sood, Vandana Midha, Varun Gupta, Gourdas Choudhuri, Vineet Ahuja
Indian Journal of Gastroenterology.2019; 38(1): 44. CrossRef
Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim
The Korean Journal of Gastroenterology.2019; 74(3): 168. CrossRef

8,278 View
199 Download
31 Web of Science
36 Crossref

IBD

Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis: Saya Tsuda, Reiko Kunisaki, Jun Kato, Mayu Murakami, Masafumi Nishio, Tsuyoshi Ogashiwa, Takeichi Yoshida, Hideaki Kimura, Masayuki Kitano; Intest Res 2018;16(4):579-587. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00021

Abstract PDF PubReader ePub

Background/Aims
In clinical practice, colonoscopy has been regarded as the gold standard for the evaluation of disease severity as well as mucosal healing in ulcerative colitis (UC). Some activity indices incorporating patient symptoms as parameters have been shown to reflect the endoscopic activity of UC. The aim of this study was to examine whether self-reported symptoms with visual analog scales (VAS) can predict endoscopic activity.
Methods
A cross-sectional study of 150 UC patients who underwent colonoscopy with submission of VAS scores of 4 symptoms: general condition, bloody stools, stool form, and abdominal pain (0: no symptoms, 10: the most severe symptoms). Each VAS score was compared with colonoscopic activity assessed with the Mayo endoscopic subscore (MES).
Results
All VAS scores were significantly correlated with the endoscopic severity (Spearman correlation coefficients of general condition, bloody stools, stool form, and abdominal pain: 0.63, 0.64, 0.58, and 0.43, respectively). Mucosal healing defined as MES 0 alone was predicted by VAS score <1.5 on general condition or 0 on bloody stools with sensitivity of 0.84 and 0.76 and specificity of 0.66 and 0.76, respectively. Additionally, VAS score <2.5 on stool form predicted active lesions in distal colorectum alone with sensitivity of 0.67 and specificity of 0.66, suggesting that this item could predict the indication of topical therapy.
Conclusions
Self-reported VAS scores on symptoms were correlated with endoscopic activity of UC. To clarify the relationship between VAS and mucosal healing, further validation studies are needed.

Citations

Citations to this article as recorded by

Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations
Stefan Schreiber, Silvio Danese, Axel Dignass, Eugeni Domènech, Massimo C Fantini, Marc Ferrante, Jonas Halfvarson, Ailsa Hart, Fernando Magro, Charlie W Lees, Salvo Leone, Marieke J Pierik, Michele Peters, Polly Field, Helen Fishpool, Laurent Peyrin-Biro
Journal of Crohn's and Colitis.2024; 18(1): 91. CrossRef
Anxiety and care experiences in adolescents with chronic health conditions: an international, longitudinal study across the transfer of care
Anna Alanen, Mira Kallio, Evelyn Culnane, Mari Koivisto, Miko Pasanen, Sanna Salanterä, Susan Sawyer, Silja Kosola
BMJ Paediatrics Open.2024; 8(1): e002836. CrossRef
Bridge study protocol: an international, observational cohort study on the transition of healthcare for adolescents with chronic conditions
Silja Kosola, Evelyn Culnane, Hayley Loftus, Anna Tornivuori, Mira Kallio, Michelle Telfer, Päivi J Miettinen, Kaija-Leena Kolho, Kristiina Aalto, Taneli Raivio, Susan Sawyer
BMJ Open.2021; 11(6): e048340. CrossRef
Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
Gian Paolo Caviglia, Federico De Blasio, Marta Vernero, Angelo Armandi, Chiara Rosso, Giorgio Maria Saracco, Elisabetta Bugianesi, Marco Astegiano, Davide Giuseppe Ribaldone
Journal of Clinical Medicine.2021; 10(21): 4961. CrossRef
Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study
Minkyung Han, Yoon Suk Jung, Jae Hee Cheon, Sohee Park
Yonsei Medical Journal.2020; 61(5): 382. CrossRef
Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?
Emma M van Andel, Brechtje D M Koopmann, Femke Crouwel, Casper G Noomen, Nanne K H de Boer, Dirk P van Asseldonk, Lidwine B Mokkink
Journal of Crohn's and Colitis.2020; 14(9): 1299. CrossRef
The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
Marta Vernero, Federico De Blasio, Davide Giuseppe Ribaldone, Elisabetta Bugianesi, Rinaldo Pellicano, Giorgio Maria Saracco, Marco Astegiano, Gian Paolo Caviglia
Journal of Clinical Medicine.2020; 9(12): 3941. CrossRef
Prediction of treatment outcome and relapse in inflammatory bowel disease
Jun Kato, Takeichi Yoshida, Sakiko Hiraoka
Expert Review of Clinical Immunology.2019; 15(6): 667. CrossRef

6,152 View
117 Download
8 Web of Science
8 Crossref

IBD

Medication non-adherence in inflammatory bowel diseases is associated with disability: Jonathan Perry, Andy Chen, Viraj Kariyawasam, Glen Collins, Chee Choong, Wei Ling Teh, Nikola Mitrev, Friedbert Kohler, Rupert Wing Loong Leong; Intest Res 2018;16(4):571-578. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00033

Abstract PDF PubReader ePub

Background/Aims
Medication non-adherence is common in inflammatory bowel diseases (IBD). The short-term consequences of non-adherence include increased disease relapse but the long-term impact upon patients in terms of daily functional impairment are less well characterized. Identifying negative outcomes, such as disability, may encourage adherence.
Methods
Consecutive ambulatory IBD subjects completed the Medication Adherence Rating Scale (MARS; non-adherence defined as ≤16), Inflammatory Bowel Diseases Disability Index (IBD-DI; disability: <3.5) and Beliefs about Medicines Questionnaire (high necessity/concerns: ≥16). The primary outcome was the association between medication non-adherence and disability. Secondary outcomes were the predictors of these outcomes.
Results
A total of 173 subjects on IBD maintenance medications were recruited (98 Crohn’s disease, 75 ulcerative colitis: median IBD-DI, –5.0; interquartile range [IQR], –14.0 to 4.0 and median MARS, 19.0; IQR, 18 to 20) of whom 24% were non-adherent. Disability correlated significantly with medication non-adherence (r=0.38, P<0.0001). Median IBD-DI for non-adherers was significantly lower than adherers (–16.0 vs. –2.0, P<0.0001). Predictors of disability included female sex (P=0.002), previous hospitalization (P=0.023), management in a referral hospital clinic (P=0.008) and medication concerns (P<0.0001). Non-adherence was independently associated with difficulty managing bowel movements (odds ratio [OR], 3.71; 95% confidence interval [CI], 1.50–9.16, P=0.005), rectal bleeding (OR, 2.69; 95% CI, 1.14–6.36; P=0.024) and arthralgia/arthritis (OR, 2.56; 95% CI, 1.11–5.92; P=0.028).
Conclusions
Medication non-adherence was associated with significantly increased disability in IBD. Female gender, higher disease severity and medication concerns were additional predictors of disability.

Citations

Citations to this article as recorded by

Understanding Medication Nonadherence in Crohn’s Disease Patients: A Qualitative Evaluation
Robert E Brady, Jessica K Salwen-Deremer, Natalie C Tunnell, Michael W Winter
Inflammatory Bowel Diseases.2024; 30(11): 2046. CrossRef
Attitudes to medication and effects of IBD nursing service among patients with inflammatory bowel disease in Taiwan
Chen‐Ta Yang, Tsui‐Chun Hsu, Yang‐Yuan Chen, Siou‐Ping Huang, Hsu‐Heng Yen
Advances in Digestive Medicine.2024; 11(3): 162. CrossRef
COMPLIANCE AND QUALITY OF LIFE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
R.J. JAMOLOVA, D.K. MUKHABBATOV, D.T. RAKHMONOV, S.G. ALI-ZADE
AVICENNA BULLETIN.2024; 26(1): 76. CrossRef
High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease
Esma H. San, Angelique Egberts, Caroline W. Th. van Dijck - van Boetzelaer, Rachel L. West, Erwin C. Vasbinder
European Journal of Clinical Pharmacology.2024; 80(7): 1089. CrossRef
MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations
Ferdinando D'Amico, Francesca Lusetti, Laurent Peyrin-Biroulet, Silvio Danese
Digestive and Liver Disease.2024; 56(9): 1425. CrossRef
Motivational Interviewing as a Strategy to Improve Adherence in IBD Treatment: An Integrative Review Amidst COVID-19 Disruptions
Caterina Mercuri, Maria Catone, Vincenzo Bosco, Assunta Guillari, Teresa Rea, Patrizia Doldo, Silvio Simeone
Healthcare.2024; 12(12): 1210. CrossRef
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study
Patrick Gagnon-Sanschagrin, Myrlene Sanon, Mikhaïl Davidson, Cynthia Willey, Sumesh Kachroo, Timothy Hoops, Dominik Naessens, Annie Guerin, Martin Cloutier
Journal of Medical Economics.2024; 27(1): 931. CrossRef
A Practical Approach to Identify Non-Adherence to Mesalamine Therapy in Inflammatory Bowel Disease
Filippo Vernia, Giorgia Burrelli Scotti, Raffaele Borghini, Mario Muselli, Stefano Necozione, Giovanni Moretta, Lorenza Scurti, Giuseppe Donato
Gastroenterology Insights.2024; 15(3): 754. CrossRef
Use of Complementary and Alternative Therapies in People with Inflammatory Bowel Disease
Laura Frank, Kelly Lambert
International Journal of Environmental Research and Public Health.2024; 21(9): 1140. CrossRef
A Retrospective Cohort Study of Clinical Features and Treatment Patterns With Ustekinumab in Patients With Crohn Disease Utilizing a Health Care Database in Japan
Yanfang Liu, Choo Hua Goh, Hong Qiu, Kuan-Chih Huang, Hsingwen Chung, Carine Saadoun
Annals of Pharmacotherapy.2023; 57(9): 1053. CrossRef
Development and implementation of a laboratory monitoring dashboard to reduce treatment gaps in inflammatory bowel disease
Miranda Kozlicki, Bridget Lynch, Tony Donoho, Patrick Nichols, Autumn D Zuckerman
American Journal of Health-System Pharmacy.2023; 80(Supplement): S55. CrossRef
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease
Edward V. Loftus, Jenny Griffith, Ezequiel Neimark, Alexandra Song, Kori Wallace, Sujani Nannapaneni, Ji Zhou, Rachel Byrne, Kristina Kligys, Yinuo Pang, Xiaomei Liao, Jasmina Kalabic, Marla Dubinsky
Advances in Therapy.2023; 40(5): 2311. CrossRef
Development and Validation of a Remote Monitoring Tool for Assessment of Mild, Moderate, and Severe Infections in Inflammatory Bowel Disease
Ashkan Rezazadeh Ardabili, Dirk van Esser, Dion Wintjens, Mia Cilissen, Debbie Deben, Zlatan Mujagic, Fritzi Russ, Laurents Stassen, Adriaan A Van Bodegraven, Dennis Wong, Bjorn Winkens, Daisy Jonkers, Mariëlle Romberg-Camps, Marie J Pierik
Journal of Crohn's and Colitis.2023; 17(7): 1079. CrossRef
Factors contributing to flares of ulcerative colitis in North India- a case-control study
Vishavdeep Singh Rana, Gaurav Mahajan, Amol N. Patil, Anupam K. Singh, Vaneet Jearth, Aravind Sekar, Harjeet Singh, Atul Saroch, Usha Dutta, Vishal Sharma
BMC Gastroenterology.2023;[Epub] CrossRef
An education‐based telehealth group improves the management and clinical outcomes of patients with inflammatory bowel disease in China (THEIM study)
Jian Kang, Juan Su, Jing Wang, Haixia Ren, Anning Yin, Jiao Li, Qian Zhou, Yang Wang, Peng Zhu, Liping Zou, Wei Wang, Zhishun Tang, Weiguo Dong, Yijuan Ding, Ping An
United European Gastroenterology Journal.2023; 11(10): 960. CrossRef
Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening
Zohar Ben-Shatach, Tomer Ziv-Baran, Ella Fudim, Miri Yavzori, Orit Picard, Asaf Levartovsky, Limor Selinger, Batia Weiss, Uri Kopylov, Rami Eliakim, Bella Ungar
Therapeutic Advances in Gastroenterology.2022;[Epub] CrossRef
Medication Adherence and Its Influencing Factors Among Inflammatory Bowel Disease Patients in China
Fen Xu, Juping Tang, Zhiping Zhu, Yan Chen, Wen Hu, Sha Lu, Yunxian Zhou, Ding Lin
International Journal of General Medicine.2022; Volume 15: 4141. CrossRef
Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn’s Disease Initiated on Biologic or Conventional Agents
Dominic Pilon, Zhijie Ding, Erik Muser, Ameur M Manceur, Maude Vermette-Laforme, Marie-Hélène Lafeuille, Patrick Lefebvre
Crohn's & Colitis 360.2022;[Epub] CrossRef
Medication adherence in women with IBD of childbearing age likely associated with disease knowledge
Robyn Laube, Christian Selinger, Rupert W. Leong
Therapeutic Advances in Gastroenterology.2022;[Epub] CrossRef
Utility of the MARS-5 in Assessing Medication Adherence in IBD
James K Stone, Leigh Anne Shafer, Lesley A Graff, Lisa Lix, Kelcie Witges, Laura E Targownik, Clove Haviva, Kathryn Sexton, Charles N Bernstein
Inflammatory Bowel Diseases.2021; 27(3): 317. CrossRef
Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes
Chikako Watanabe, Masakazu Nagahori, Toshimitsu Fujii, Kaoru Yokoyama, Naoki Yoshimura, Taku Kobayashi, Hirokazu Yamagami, Kazuya Kitamura, Kagaya Takashi, Shiro Nakamura, Makoto Naganuma, Shunji Ishihara, Motohiro Esaki, Maria Yonezawa, Reiko Kunisaki, A
Digestive Diseases and Sciences.2021; 66(2): 577. CrossRef
Selected psychological predictors of medication adherence in the older adults with chronic diseases
Magdalena Gruszczyńska, Julia Wyszomirska, Anna Daniel‐Sielańczyk, Monika Bąk‐Sosnowska
Nursing Open.2021; 8(1): 317. CrossRef
Impacto de la pandemia covid-19 en la adherencia al tratamiento en pacientes con enfermedad inflamatoria intestinal: experiencia de un centro terciario en Chile
Rodrigo Quera, Daniela Simian, Lilian Flores, Patricio Ibáñez, Carolina Figueroa
Gastroenterología y Hepatología.2021; 44(9): 654. CrossRef
Adherence to Subcutaneous Biological Therapies in Patients with Inflammatory Rheumatic Diseases and Inflammatory Bowel Disease: A Systematic Review
Juan C Nieto, Claudia Arajol, Loreto Carmona, Carlos Marras, Luis Cea-Calvo
Immunotherapy.2021; 13(5): 433. CrossRef
Researching Interventions to Improve Medication Adherence in Ulcerative Colitis Patients
Mila Palma Pacheco, Flora Maria Lorenzo Fortes, Raquel Rocha dos Santos, Genoile Oliveira Santana Silva
Journal of Coloproctology.2021; 41(01): 096. CrossRef
Persistence as a Robust Indicator of Medication Adherence-Related Quality and Performance
Enrica Menditto, Caitriona Cahir, Sara Malo, Isabel Aguilar-Palacio, Marta Almada, Elisio Costa, Anna Giardini, María Gil Peinado, Mireia Massot Mesquida, Sara Mucherino, Valentina Orlando, Carlos Luis Parra-Calderón, Enrique Pepiol Salom, Przemyslaw Kard
International Journal of Environmental Research and Public Health.2021; 18(9): 4872. CrossRef
Effect of point‐of‐care gastrointestinal ultrasound on decision‐making and management in inflammatory bowel disease
Antony B. Friedman, Anil Asthana, Simon R. Knowles, Aphra Robbins, Peter R. Gibson
Alimentary Pharmacology & Therapeutics.2021; 54(5): 652. CrossRef
Impact of the COVID-19 pandemic on treatment adherence in patients with inflammatory bowel disease: Experience of a tertiary hospital in Chile
Rodrigo Quera, Daniela Simian, Lilian Flores, Patricio Ibáñez, Carolina Figueroa
Gastroenterología y Hepatología (English Edition).2021; 44(9): 654. CrossRef
Adherence to treatment in patients with inflammatory bowel disease
K. A. Andreev, A. V. Gorbenko, Yu. P. Skirdenko, N. A. Nikolaev, M. A. Livzan, G. R. Bikbavova, M. M. Fedorin
Bulletin of Siberian Medicine.2021; 20(3): 120. CrossRef
Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study
Juan Lasa, Gustavo Correa, Claudia Fuxman, Laura Garbi, Maria Eugenia Linares, Pablo Lubrano, Astrid Rausch, Martin Toro, Martin Yantorno, Ignacio Zubiaurre, Laurent Peyrin-Biroulet, Pablo Olivera
Gastroenterology Research and Practice.2020; 2020: 1. CrossRef
Knowledge of disease and self‐management of adolescents with inflammatory bowel diseases
Alex Krauthammer, Tal Harel, Noam Zevit, Dror S. Shouval, Raanan Shamir, Batia Weiss
Acta Paediatrica.2020; 109(10): 2119. CrossRef
The burden of cost in inflammatory bowel disease: a medical economic perspective
Jonathan A. Beard, Benjamin H. Click
Current Opinion in Gastroenterology.2020; 36(4): 310. CrossRef
İnflamatuar Bağırsak Hastalıkları Olan Bireylerde İlaç Uyumu ve Yaşam Kalitesi
Nazli ÖZTÜRK, Yasemin YILDIRIM
Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi.2020; 2(3): 192. CrossRef
Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus
Marco Daperno, Alessandro Armuzzi, Silvio Danese, Walter Fries, Giuseppina Liguori, Ambrogio Orlando, Claudio Papi, Mariabeatrice Principi, Fernando Rizzello, Angelo Viscido, Paolo Gionchetti
Gastroenterology Research and Practice.2019; 2019: 1. CrossRef
The Development of a Screening Tool to Identify and Classify Nonadherence in Inflammatory Bowel Disease
Aria Zand, Audrey Nguyen, Zack Stokes, Welmoed van Deen, Courtney Reynolds, Magdalena Dimitrova, Ariela Khandadash, Miriam Dvorsky, Jenny Sauk, Eric Esrailian, Daniel Hommes
Crohn's & Colitis 360.2019;[Epub] CrossRef
Adherence to therapy of patients with inflammatory bowel diseases
A I Parfenov, A V Kagramanova, A F Babayan, O V Knyazev
Terapevticheskii arkhiv.2018; 90(12): 4. CrossRef

8,246 View
171 Download
33 Web of Science
36 Crossref

IBD

Usefulness of fecal immunochemical test and fecal calprotectin for detection of active ulcerative colitis: Dong Ju Kim, Yoon Mi Jeoun, Dong-won Lee, Ja Seol Koo, Sang Woo Lee; Intest Res 2018;16(4):563-570. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00020

Abstract PDF PubReader ePub

Background/Aims
Ulcerative colitis undergoes periods of exacerbation and remission. Fecal calprotectin levels increase with gut inflammation and correlate with endoscopic disease activity in ulcerative colitis. Intestinal blood loss and fecal immunochemical test levels also correlate with endoscopic disease activity. This study statistically evaluated the usefulness of fecal calprotectin, fecal immunochemical test, and C-reactive protein (CRP) as markers of disease activity.
Methods
A total 106 ulcerative colitis patients who underwent endoscopy and fecal calprotectin, fecal immunochemical test, and CRP testing, from March 2015 to August 2016, were retrospectively reviewed. Disease activity was assessed using a partial Mayo score and Mayo endoscopic score. The ability of fecal and serologic tests to reflect endoscopic disease severity was statistically evaluated.
Results
Among 106 patients, 68 underwent endoscopy and stool study within 2 weeks. In patients with mild to severe activity, fecal immunochemical test and fecal calprotectin were superior to CRP at Mayo endoscopic score detection rate. The area under the curves of fecal immunochemical test and fecal calprotectin for the detection of Mayo endoscopic score ≥1 were 0.956 and 0.942, respectively, and were superior to that of CRP (0.756). At Mayo endoscopic score, the effects of combination of fecal immunochemical test and CRP or fecal calprotectin and CRP were found to be higher than those of the independent fecal immunochemical test or fecal calprotectin.
Conclusions
Fecal immunochemical test and fecal calprotectin can effectively detect active ulcerative colitis better than remission. As these markers reflect the status of mucosal inflammation, they may reduce the requirement for invasive endoscopic examination.

Citations

Citations to this article as recorded by

Histologic features and predicting prognosis in ulcerative colitis patients with mild endoscopic activity
Seung Yong Shin, Hee Sung Kim, Kisung Kim, Chang Won Choi, Jung Min Moon, Jeong Wook Kim, Hyun Jin Joo, Jeongkuk Seo, Muhyeon Sung, Chang Hwan Choi
The Korean Journal of Internal Medicine.2024; 39(1): 68. CrossRef
Prostaglandin E‐major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase
Toshiyuki Sakurai, Yoshihiro Akita, Haruna Miyashita, Ryosuke Miyazaki, Yuki Maruyama, Tomoko Saito, Mariko Shimada, Takuji Yamasaki, Seiji Arhihiro, Tomohiro Kato, Tomokazu Matsuura, Masahiro Ikegami, Isao Okayasu, Masayuki Saruta
Journal of Gastroenterology and Hepatology.2022; 37(5): 847. CrossRef
Alternative diagnoses and demographics associated with a raised quantitative faecal immunochemical test in symptomatic patients
Mark S Johnstone, Gillian Miller, Grace Pang, Paul Burton, Georgios Kourounis, Jack Winter, Emilia Crighton, David Mansouri, Paul Witherspoon, Karen Smith, Stephen T McSorley
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2022; 59(4): 277. CrossRef
Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
Nagesh Kamat, Sudheer K Vuyyuru, Saurabh Kedia, Pabitra Sahu, Bhaskar Kante, Peeyush Kumar, Mukesh Kumar Ranjan, Mukesh Kumar Singh, Sambuddha Kumar, Vikas Sachdev, Govind Makharia, Vineet Ahuja
Intestinal Research.2022; 20(2): 269. CrossRef
Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis
Mao Matsubayashi, Taku Kobayashi, Shinji Okabayashi, Masaru Nakano, Shintaro Sagami, Ryo Ozaki, Hiroki Kiyohara, Hiromu Morikubo, Kunio Asonuma, Yusuke Miyatani, Shin Maeda, Toshifumi Hibi
Journal of Gastroenterology and Hepatology.2021; 36(4): 943. CrossRef
Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?
Gabriele Dragoni, Tommaso Innocenti, Andrea Galli
Digestive Diseases.2021; 39(3): 190. CrossRef
Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease
Jack S. Cornish, Elisa Wirthgen, Jan Däbritz
Frontiers in Medicine.2020;[Epub] CrossRef
Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis
Hsu-Heng Yen, Mei-Wen Chen, Yu-Yao Chang, Hsuan-Yuan Huang, Tsui-Chun Hsu, Yang-Yuan Chen
PeerJ.2020; 8: e9537. CrossRef
What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission?
Jongbeom Shin, Sung Min Kong, Gyeol Seong, Young-Ho Kim
International Journal of Colorectal Disease.2020; 35(12): 2249. CrossRef
Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission
Natsuki Ishida, Kiichi Sugiura, Takahiro Miyazu, Satoshi Tamura, Satoshi Suzuki, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Clinical and Translational Gastroenterology.2020; 11(12): e00289. CrossRef
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases
Parambir S. Dulai, Laurent Peyrin-Biroulet, Silvio Danese, Bruce E. Sands, Axel Dignass, Dan Turner, Gerassimos Mantzaris, Juergen Schölmerich, Jean-Yves Mary, Walter Reinisch, William J. Sandborn
Gastroenterology.2019; 157(4): 1032. CrossRef

7,695 View
185 Download
11 Web of Science
11 Crossref

IBD

Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study: Shiro Nakamura, Hirotsugu Imaeda, Hiroki Nishikawa, Masaki Iimuro, Minoru Matsuura, Hideo Oka, Junsuke Oku, Takako Miyazaki, Hirohito Honda, Kenji Watanabe, Hiroshi Nakase, Akira Andoh; Intest Res 2018;16(4):554-562. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00027

Abstract PDF PubReader ePub

Background/Aims
Noninvasive objective monitoring is advantageous for optimizing treatment strategies in patients inflammatory bowel disease (IBD). Fecal calprotectin (FCP) is superior to traditional biomarkers in terms of assessing the activity in patients with IBD. However, there are the differences among several FCP assays in the dynamics of FCP. In this prospective multicenter trial, we investigated the usefulness of fecal FCP measurements in adult Japanese patients with IBD by reliable enzyme immunoassay using a monoclonal antibody.
Methods
We assessed the relationship between FCP levels and disease or endoscopic activity in patients with ulcerative colitis (UC, n=64) or Crohn’s disease (CD, n=46) compared with healthy controls (HCs, n=64).
Results
FCP levels in UC patients strongly correlated with the Disease Activity Index (rs=0.676, P<0.0001) and Mayo endoscopic subscore (MES; rs=0.677, P<0.0001). FCP levels were significantly higher even in patients with inactive UC or CD compared with HCs (P=0.0068, P<0.0001). The optimal cutoff value between MES 1 and 2 exhibited higher sensitivity (94.1%). FCP levels were significantly higher in active UC patients than in inactive patients (P<0.001), except those with proctitis. The Crohn’s Disease Activity Index tended to correlate with the FCP level (rs=0.283, P=0.0565).
Conclusions
Our testing method using a monoclonal antibody for FCP was well-validated and differentiated IBD patients from HCs. FCP may be a useful biomarker for objective assessment of disease activity in adult Japanese IBD patients, especially those with UC.

Citations

Citations to this article as recorded by

Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021
Hiroshi Nakase, Motohiro Esaki, Fumihito Hirai, Taku Kobayashi, Katsuyoshi Matsuoka, Minoru Matsuura, Makoto Naganuma, Masayuki Saruta, Kiichiro Tsuchiya, Motoi Uchino, Kenji Watanabe, Tadakazu Hisamatsu, Akira Andoh, Shigeki Bamba, Motohiro Esaki, Mikihi
Journal of Gastroenterology.2023; 58(4): 313. CrossRef
Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine
Tomohiro Fukuda, Makoto Naganuma, Kaoru Takabayashi, Yuya Hagihara, Shun Tanemoto, Ena Nomura, Yusuke Yoshimatsu, Shinya Sugimoto, Kosaku Nanki, Shinta Mizuno, Yohei Mikami, Kayoko Fukuhara, Tomohisa Sujino, Makoto Mutaguchi, Nagamu Inoue, Haruhiko Ogata,
Journal of Gastroenterology and Hepatology.2020; 35(11): 1878. CrossRef
Clinical management for small bowel of Crohn’s disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion
Kenji Watanabe
Intestinal Research.2020; 18(4): 347. CrossRef

7,261 View
180 Download
4 Web of Science
3 Crossref

IBD

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring: Shu-Chen Wei, Chien-Chih Tung, Meng-Tzu Weng, Jau-Min Wong; Intest Res 2018;16(4):546-553. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00052

Abstract PDF PubReader ePub

Background/Aims
Fecal calprotectin (fC) level is a predictive marker of mucosal healing for patients with inflammatory bowel disease (IBD). Home fC tests are now available. We evaluated the performance of the smartphone-based IBDoc home testing system in patients with IBD and obtained their feedback as an objective patient-reported outcome.
Methods
This prospective study enrolled consecutive patients with IBD in clinical remission. fC in the same stool sample was assessed by using both the laboratory test (Quantum Blue calprotectin test) and home test (IBDoc). The correlation between the 2 tests was analyzed using the Pearson method. In addition, the patients were asked to fill a questionnaire based on their experience.
Results
Fifty-one patients with IBD (68 tests and 49 questionnaires) were included. The correlation between Quantum Blue test and IBDoc was good (r=0.776, P<0.0001). After the test, 56% patients found IBDoc easy to perform, and 96% were satisfied with it. Thirty-nine patients (80%) had a strong (>70%) probability to use it for future monitoring if the price was acceptable. By using 250 μg/g as the cutoff, the agreement between home test and laboratory results was 80%, and by using 600 μg/g as the cutoff, the agreement increased to 92%.
Conclusions
The correlation between the laboratory and home tests was good. Most patients found the home test to be feasible and easy to use and preferred it over laboratory test and endoscopy for monitoring. Therefore, the home test could be used as an objective patient-reported outcome.

Citations

Citations to this article as recorded by

Performance evaluation of a smartphone-based home test for fecal calprotection
Simon Michaelis, Anna Hochfellner, Christopher Schneider, Wolfgang J. Schnedl, Andreas Baranyi, Dietmar Enko
Clinical Chemistry and Laboratory Medicine (CCLM).2025; 63(1): 139. CrossRef
Blood self-sampling: friend or foe?
Mario Plebani
Clinical Chemistry and Laboratory Medicine (CCLM).2025; 63(1): 1. CrossRef
Validation of rapid fecal calprotectin assay using particle enhanced turbidimetric immunoassay for inflammatory bowel disease
Akihiko Oka, Kousaku Kawashima, Kenichi Kishimoto, Satoshi Kotani, Mai Fukunaga, Nobuhiko Fukuba, Yoshiyuki Mishima, Naoki Oshima, Norihisa Ishimura, Muyiwa Awoniyi, Shunji Ishihara
Scientific Reports.2024;[Epub] CrossRef
iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
Ferdinando D’Amico, Fernando Magro, Benedicte Caron, Axel Dignass, Vipul Jairath, Ailsa Hart, Paulo Gustavo Kotze, Kristine Paridaens, Sameer Al Awadhi, Taku Kobayashi, Britta Siegmund, Laurent Peyrin-Biroulet, Silvio Danese
Journal of Clinical Medicine.2023; 12(3): 1142. CrossRef
Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound
Rune Wilkens, Michael Dolinger, Johan Burisch, Christian Maaser
Gastroenterology.2022; 162(5): 1476. CrossRef
Post-neonatal Outcomes of Infants Born to Women with Active Trimester One Inflammatory Bowel Disease: A Pilot Study
Richard Y. Wu, Parul Tandon, Lindsy Ambrosio, Garett Dunsmore, Naomi Hotte, Levinus A. Dieleman, Shokrollah Elahi, Karen Madsen, Vivian Huang
Digestive Diseases and Sciences.2022; 67(11): 5177. CrossRef
Inflammatory bowel disease biomarkers
Dandan Liu, Varma Saikam, Katie A. Skrada, Didier Merlin, Suri S. Iyer
Medicinal Research Reviews.2022; 42(5): 1856. CrossRef
Urine and Serum Metabolomic Profiles Differ by Disease Activity in Pregnant Women With Inflammatory Bowel Diseases
Richard Y. Wu, Parul Tandon, Joyce S. Oh, Lindsy Ambrosio, Naomi Hotte, Binal Shah-Gandhi, Karen L. Madsen, Levinus A. Dieleman, Shokrollah Elahi, Karen I. Kroeker, Vivian Huang
Gastro Hep Advances.2022; 1(6): 993. CrossRef
Elevated IL-6 and IL-22 in Early Pregnancy Are Associated with Worse Disease Course in Women with Inflammatory Bowel Disease
Richard Y. Wu, Karren Xiao, Naomi Hotte, Parul Tandon, Yesmine Elloumi, Lindsy Ambrosio, Garett Dunsmore, Shokrollah Elahi, Karen I. Kroeker, Levinus A. Dieleman, Karen L. Madsen, Vivian Huang
International Journal of Molecular Sciences.2022; 23(18): 10281. CrossRef
Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease
Isak Östlund, Mårten Werner, Pontus Karling
Scandinavian Journal of Gastroenterology.2021; 56(1): 38. CrossRef
How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician
Júlio Maria Fonseca Chebli, Natália Sousa Freitas Queiroz, Adérson Omar Mourão Cintra Damião, Liliana Andrade Chebli, Márcia Henriques de Magalhães Costa, Rogério Serafim Parra
World Journal of Gastroenterology.2021; 27(11): 1022. CrossRef
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
Ferdinando D'Amico, David T. Rubin, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Taku Kobayashi, Pablo A. Olivera, Peter Bossuyt, Lieven Pouillon, Edouard Louis, Eugeni Domènech, Subrata Ghosh, Silvio Danese, Laurent Peyrin‐Biroulet
United European Gastroenterology Journal.2021; 9(4): 451. CrossRef
A Patient Self-Made Point-of-Care Fecal Test Improves Diagnostic Accuracy Compared with Fecal Calprotectin Alone in Inflammatory Bowel Disease Patients
Gonzalo Hijos-Mallada, Raul Velamazán, Raúl Marti, Eduardo Chueca, Samantha Arechavaleta, Alberto Lué, Fernando Gomollón, Angel Lanas, Carlos Sostres
Diagnostics.2021; 11(12): 2323. CrossRef
Real-life utility and diagnostic accuracy of a home-performed fecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under maintenance treatment with adalimumab
Eleni Orfanoudaki, Ioannis Drygiannakis, Eirini Theodoraki, Kalliopi Foteinogiannopoulou, Aikaterini Mantaka, Ioannis E. Koutroubakis
European Journal of Gastroenterology & Hepatology.2021; 33(1S): e777. CrossRef
Fecal calprotectin predicts complete mucosal healing in patients with ulcerative colitis: Systematic review and meta‑analysis
Zhongsheng Cao, Chenglong Ye, Lunan Li, Xiaoge Geng, Wensheng Pan, Jiyong Jing
World Academy of Sciences Journal.2021;[Epub] CrossRef
The effect of a mindfulness-based therapy on different biomarkers among patients with inflammatory bowel disease: a randomised controlled trial
Rafael González-Moret, Ausias Cebolla, Xavier Cortés, Rosa M. Baños, Jaime Navarrete, José Enrique de la Rubia, Juan Francisco Lisón, José Miguel Soria
Scientific Reports.2020;[Epub] CrossRef
Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults
Małgorzata Krzystek-Korpacka, Radosław Kempiński, Mariusz Bromke, Katarzyna Neubauer
Diagnostics.2020; 10(6): 367. CrossRef
What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission?
Jongbeom Shin, Sung Min Kong, Gyeol Seong, Young-Ho Kim
International Journal of Colorectal Disease.2020; 35(12): 2249. CrossRef
Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience
Ferdinando D’Amico, Patrick Netter, Cedric Baumann, Muriel Veltin, Camille Zallot, Isabelle Aimone-Gastin, Silvio Danese, Laurent Peyrin-Biroulet
Journal of Clinical Medicine.2020; 9(9): 2697. CrossRef
Calprotectin in inflammatory bowel disease
Fatemeh Khaki-Khatibi, Durdi Qujeq, Mehrdad Kashifard, Soheila Moein, Mahmood Maniati, Mostafa Vaghari-Tabari
Clinica Chimica Acta.2020; 510: 556. CrossRef
Remote Monitoring Empowerment of Patients with IBDs during the SARS-CoV-2 Pandemic
Mauro Mastronardi, Margherita Curlo, Maurizio Polignano, Natalino Vena, Daniela Rossi, Gianluigi Giannelli
Healthcare.2020; 8(4): 377. CrossRef
Usability of IBDoc, a Novel Fecal Calprotectin Home-Based Rapid Test in Clinical Practice
Mia Jülke Røer, Milada Cvancarova Småstuen, Arne Gustav Røseth
Point of Care: The Journal of Near-Patient Testing & Technology.2019; 18(3): 85. CrossRef
Home-based fecal calprotectin test is expected to play an important role in patients with inflammatory bowel diseases
Young-Ho Kim
Intestinal Research.2018; 16(4): 507. CrossRef

11,105 View
173 Download
23 Web of Science
23 Crossref

IBD

IBD2020 global forum: results of an international patient survey on quality of care: Peter Irving, Johan Burisch, Richard Driscoll, Mats Olsson, John R Fullarton, Barry S Rodgers-Gray, Simon PL Travis; Intest Res 2018;16(4):537-545. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00041

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
IBD2020 is a global forum for standards of care in inflammatory bowel disease (IBD). The aim of the IBD2020 survey was to identify and describe variations in quality care of IBD.
Methods
Patients with IBD from Finland, Italy, France, Canada, Germany, UK, Spain and Sweden were surveyed during 2013 to 2014, covering: disease characteristics; impact on life and work; organization and perceived quality of care.
Results
Seven thousand five hundred and seven patients participated (median age, 39 years [range, 10–103 years]; 2,354 male [31.4%]), including 4,097 (54.6%) with Crohn’s disease (CD) and 3,410 (45.4%) with ulcerative colitis (UC). Median time from symptom onset to diagnosis was 1 year for both CD (range, 0–47 years) and UC (range, 0–46 years), with no clear evidence of improvement in diagnostic delay over the preceding 24 years. Half of the patients (3,429; 50.0%) rated their care as “excellent” or “very good,” with similar results for CD and UC across countries. Five factors were significantly (P<0.01) associated with perceived good quality of care: quality of specialist communication; review consultation being long enough; failure to share information; no access to a dietician; speed of advice.
Conclusions
The IBD2020 survey has highlighted areas related to quality of care of IBD from the patients’ perspective, with scope for improvement.

Citations

Citations to this article as recorded by

Children and Young Adults With Inflammatory Bowel Disease Have an Increased Incidence and Risk of Developing Mental Health Conditions: A UK Population-Based Cohort Study
Rachel Cooney, Daniel Tang, Kevin Barrett, Richard K Russell
Inflammatory Bowel Diseases.2024; 30(8): 1264. CrossRef
Impact of mental health comorbidity in children and young adults with inflammatory bowel disease: a UK population-based cohort study
Rachel Cooney, Kevin Barrett, Richard K Russell
BMJ Open.2024; 14(2): e080408. CrossRef
Sources of diagnostic delay for people with Crohn’s disease and ulcerative colitis: Qualitative research study
Valérie Pittet
PLOS ONE.2024; 19(6): e0301672. CrossRef
Systematic review with meta‐analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease
Nishani Jayasooriya, Samantha Baillie, Jonathan Blackwell, Alex Bottle, Irene Petersen, Hanna Creese, Sonia Saxena, Richard C. Pollok
Alimentary Pharmacology & Therapeutics.2023; 57(6): 635. CrossRef
Diagnostic delay in adult inflammatory bowel disease: A systematic review
Eleanor Cross, Benjamin Saunders, Adam D. Farmer, James A. Prior
Indian Journal of Gastroenterology.2023; 42(1): 40. CrossRef
The Experiences of Older Adults Living With Inflammatory Bowel Disease
Noelle Rohatinsky, Brooke Russell, Kevin B. Read
Gastroenterology Nursing.2023; 46(4): 296. CrossRef
Unmet Challenges in Patients with Crohn’s Disease
Katharina M Scheurlen, Mary A Parks, Anne Macleod, Susan Galandiuk
Journal of Clinical Medicine.2023; 12(17): 5595. CrossRef
The 2023 Impact of Inflammatory Bowel Disease in Canada: Access to and Models of Care
Holly Mathias, Noelle Rohatinsky, Sanjay K Murthy, Kerri Novak, M Ellen Kuenzig, Geoffrey C Nguyen, Sharyle Fowler, Eric I Benchimol, Stephanie Coward, Gilaad G Kaplan, Joseph W Windsor, Charles N Bernstein, Laura E Targownik, Juan-Nicolás Peña-Sánchez, K
Journal of the Canadian Association of Gastroenterology.2023; 6(Supplement): S111. CrossRef
Inflammatory bowel diseases: Transformation of representations. A review
Igor V. Maev, Igor G. Bakulin, Maria I. Skalinskaya, Ekaterina V. Skazyvaeva
Terapevticheskii arkhiv.2023; 95(12): 1064. CrossRef
Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD
Nurulamin M Noor, Paula Sousa, Stéphane Paul, Xavier Roblin
Inflammatory Bowel Diseases.2022; 28(8): 1254. CrossRef
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
Axel U. Dignass, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, Jae Hee Cheon, John R. Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R. Moschen, Neeraj Narula, Grazyna Rydzewska, Simon P. L. Travis
Scandinavian Journal of Gastroenterology.2022; 57(4): 424. CrossRef
Inflammatory bowel disease patient‐reported quality assessment should drive service improvement: a national survey of UK IBD units and patients
A. Barney Hawthorne, Jackie Glatter, Jonathan Blackwell, Rachel Ainley, Ian Arnott, Kevin J. Barrett, Graham Bell, Matthew J. Brookes, Melissa Fletcher, Rafeeq Muhammed, Alan M. Nevill, Jonathan Segal, Christian P. Selinger, Anja St. Clair Jones, Lisa You
Alimentary Pharmacology & Therapeutics.2022; 56(4): 625. CrossRef
Multicriteria Decision Analysis for Updating of Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units in Spain
Xavier Calvet, Julián Panés, Javier Gallardo-Escudero, Alberto de la Cuadra-Grande, Elena Bartolomé, Laura Marín, Fernando de la Portilla, Ester Navarro-Correal, Ana Gutiérrez, Pilar Nos, Ruth Serrano, Miguel Ángel Casado, Manuel Barreiro-de Acosta, Pilar
Journal of Crohn's and Colitis.2022; 16(11): 1663. CrossRef
Patient-reported Outcomes: the ICHOM Standard Set for Inflammatory Bowel Disease in Real-life Practice Helps Quantify Deficits in Current Care
Darren Wong, Lawrence Matini, Andrey Kormilitzin, Ramona Kantschuster, Daniel Martin Simadibrata, Sara Lyden, Jean Wilson, Oliver A Brain, Rebecca Palmer, Tim Ambrose, Jack Satsangi, Matthew South, John Geddes, Keith Bodger, Simon P L Travis, Alissa Walsh
Journal of Crohn's and Colitis.2022; 16(12): 1874. CrossRef
Quality of care in patients with inflammatory bowel disease from a public health center in Brazil
Debora Mayumi Takamune, Giovana Signorelli Astolfi Cury, Giulia Ferrás, Giedre Soares Prates Herrerias, Adriana Rivera, Jaqueline Ribeiro Barros, Julio Pinheiro Baima, Rogerio Saad-Hossne, Ligia Yukie Sassaki
World Journal of Clinical Cases.2022; 10(33): 12184. CrossRef
Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians
David T Rubin, Ailsa Hart, Remo Panaccione, Alessandro Armuzzi, Ulla Suvanto, J Jasper Deuring, John Woolcott, Joseph C Cappelleri, Kathy Steinberg, Laura Wingate, Stefan Schreiber
Inflammatory Bowel Diseases.2021; 27(7): 1096. CrossRef
The new frontier: Certifying quality standards in the inflammatory bowel disease care
Gionata Fiorino, Silvio Danese
United European Gastroenterology Journal.2021; 9(7): 745. CrossRef
Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK
Rukshana Kapasi, Jackie Glatter, Christopher A Lamb, Austin G Acheson, Charles Andrews, Ian D Arnott, Kevin J Barrett, Graham Bell, Guaraang Bhatnagar, Stuart Bloom, Matthew James Brookes, Steven R Brown, Nicola Burch, Andy Burman, Kay Crook, JR Fraser Cu
Frontline Gastroenterology.2020; 11(3): 178. CrossRef
Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn’s and Colitis Organisation [ECCO] Position Paper
Gionata Fiorino, Theodore Lytras, Lisa Younge, Catarina Fidalgo, Sofie Coenen, Maria Chaparro, Mariangela Allocca, Ian Arnott, Peter Bossuyt, Johan Burisch, Marjo Campmans-Kuijpers, Lissy de Ridder, Axel Dignass, Ciara Drohan, Roger Feakins, Daniela Gilar
Journal of Crohn's and Colitis.2020; 14(8): 1037. CrossRef
Mejora de la atención al paciente con enfermedad inflamatoria intestinal: Proyecto KOAN
Jordi Guardiola, Laura Marín, Javier P. Gisbert, Fernando Gomollón, Jordi Cohen, Carmen Conde
Economía de la Salud.2019;[Epub] CrossRef

7,833 View
197 Download
18 Web of Science
20 Crossref

Microbiota

Development and diversity of lactic acid producing bacteria and bifidobacteria in healthy full term Indian infants from Himachal Pradesh: Sampan Attri, Rishi Mahajan, Gunjan Goel; Intest Res 2018;16(4):529-536. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00050

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
The initial microbial colonization is a crucial step for the healthy development of an infant. Previous studies from India reported the dominance of target microbial species among Indian infants without any analysis on the diversity of target groups. This is the first study from India with an objective to investigate the establishment and diversity of lactic acid producing bacteria (LAB) and bifidobacteria in vaginally delivered, full term, breastfed infants for the first 4 months after birth.
Methods
Present study used polymerase chain reaction-denaturating gradient gel electrophoresis (PCR-DGGE) based sequence analysis of LAB and bifidobacteria in healthy infants. The results were used to compare the development and early colonization by LAB and bifidobacteria using diversity indices during the initial months of development of gut microbiota in infants.
Results
During the first 4 months, the Shannon diversity index (H) of LAB increased from 1.16 to 1.318 and for bifidobacteria the H increased from 0.975 to 1.293 (P<0.05). Higher Sorenson’s pair wise similarity coefficient was observed for LAB and bifidobacteria during 2nd and the 3rd month. The species of the genera Enterococcus, Streptococcus, and Lactobacillus were dominant among the LAB group whereas Bifidobacterium breve was dominant species among Bifidobacterium group.
Conclusions
Our results indicate that in breast fed infants, the microbial diversity of LAB and bifidobacteria increased during the period of study.

Citations

Citations to this article as recorded by

Development and Functions of the Infant Gut Microflora: Westernvs. Indian Infants
Lalit Bharadia, Neha Agrawal, Nandan Joshi
International Journal of Pediatrics.2020; 2020: 1. CrossRef

6,769 View
132 Download
1 Web of Science
1 Crossref

Endoscopy

Histologic discrepancy between endoscopic forceps biopsy and endoscopic mucosal resection specimens of colorectal polyp in actual clinical practice: Moon Joo Hwang, Kyeong Ok Kim, A Lim Kim, Si Hyung Lee, Byung Ik Jang, Tae Nyeun Kim; Intest Res 2018;16(3):475-483. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.475

Abstract PDF PubReader ePub

Background/Aims

We aimed to assess the rate of histologic discrepancy (HD) between endoscopic forceps biopsy (EFB) and totally resected specimens in colorectal polyp and analyze the risk factors of discordant group, especially under-diagnosis (UD) cases before complete removal of colorectal polyp.

Methods

From 2010 to 2015, a total of 290 polyps in 210 patients which had baseline pathology report before endoscopic resection (ER) were analyzed. UD cases were defined as those in which the diagnosis changed to a more advanced histologic feature after ER.

Results

A change in the final histology after ER was noted in 137 cases (47.2%), and after excluding 9 insignificant cases, 128 cases were further categorized into over-diagnosed and under-diagnosed group. UD occurred in 86 cases (29.7%) and change from benign to malignancy was noted in 26 cases (8.9%). On univariate analysis, a larger polyp size (>10 mm) was significantly associated with both HD (P<0.001) and UD (P<0.001). Regarding polyp morphology, protruding or flat was not significantly important. On multivariate analysis, polyp size >10 mm was the single most significant predictor of both HD (P<0.001) and UD (P<0.001).

Conclusions

The HD and UD rates were 47.2% and 29.7%, respectively. Polyp size >10 mm was the most important predictor of both HD and UD. We should be careful in making treatment strategy of colorectal polyp based on histologic report of EFB especially when the size of polyp is >10 mm.

Citations

Citations to this article as recorded by

Genetic Analysis of Biopsy Tissues from Colorectal Tumors in Patients with Ulcerative Colitis
Noriko Yamamoto, Yuji Urabe, Hikaru Nakahara, Takeo Nakamura, Daisuke Shimizu, Hirona Konishi, Kazuki Ishibashi, Misa Ariyoshi, Ryo Miyamoto, Junichi Mizuno, Takeshi Takasago, Akira Ishikawa, Akiyoshi Tsuboi, Hidenori Tanaka, Ken Yamashita, Yuichi Hiyama,
Cancers.2024; 16(19): 3271. CrossRef
Comparing efficacy and factors of postoperative bleeding in endoscopic mucosal resection vs coagulation for intestinal polyps
Zhiang Li, Fei Yu, Chaoqian Wang, Zhang Du
Medicine.2023; 102(37): e34941. CrossRef
“Unresectable” polyp management utilizing advanced endoscopic techniques results in high rate of colon preservation
Carey J. Wickham, Jennifer Wang, Kasim L. Mirza, Erik R. Noren, Joongho Shin, Sang W. Lee, Kyle G. Cologne
Surgical Endoscopy.2022; 36(3): 2121. CrossRef
Potential Factors Predicting Histopathologically Upgrade Discrepancies between Endoscopic Forceps Biopsy of the Colorectal Low-Grade Intraepithelial Neoplasia and Endoscopic Resection Specimens
Junbo Hong, Yining Wang, Jiangshan Deng, Miao Qi, Wei Zuo, Yuanzheng Hao, Anjiang Wang, Yi Tu, Shan Xu, Xiaodong Zhou, Xiaojiang Zhou, Guohua Li, Liang Zhu, Xu Shu, Yin Zhu, Nonghua Lv, Youxiang Chen, Li-kang Sun
BioMed Research International.2022; 2022: 1. CrossRef
Endoscopic vs optical biopsy for patients with colorectal lesions: prospective multicentral trial
K.D. Khalin, M.Yu. Agapov, E.D. Fedorov, L.V. Zvereva, N.E. Ogurchyonok, K.V. Stegnii, E.V. Ivanova, E.R. Dvoinikova, E.V. Gorbachev
Dokazatel'naya gastroenterologiya.2022; 11(3): 11. CrossRef
Long-term Outcomes of Primary Endoscopic Resection vs Surgery for T1 Colorectal Cancer: A Systematic Review and Meta-analysis
Jen-Hao Yeh, Cheng-Hao Tseng, Ru-Yi Huang, Chih-Wen Lin, Ching-Tai Lee, Po-Jen Hsiao, Tsung-Chin Wu, Liang-Tseng Kuo, Wen-Lun Wang
Clinical Gastroenterology and Hepatology.2020; 18(12): 2813. CrossRef
Prophylactic endoscopic coagulation to prevent delayed post-EMR bleeding in the colorectum: a prospective randomized controlled trial (with videos)
Hyun Seok Lee, Seong Woo Jeon, Yong Hwan Kwon, Su Youn Nam, Seonghwan Shin, Ryanghi Kim, Sohyun Ahn
Gastrointestinal Endoscopy.2019; 90(5): 813. CrossRef

8,118 View
95 Download
5 Web of Science
7 Crossref

Colorectal neoplasia

Clinical significance of carcinoembryonic antigen in peritoneal fluid detected during operation in stage I–III colorectal cancer patients: Jae Hyun Kim, Seunghun Lee, Seung Hyun Lee, Byung Kwon Ahn, Sung Uhn Baek, Won Moon, Seun Ja Park; Intest Res 2018;16(3):467-474. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.467

Abstract PDF PubReader ePub

Background/Aims

Early diagnosis of peritoneal metastases in patients with colorectal cancer (CRC) can influence patient prognosis. The aim of this study was to identify the clinical significance of carcinoembryonic antigen (CEA) in peritoneal fluid detected during operation in stage I–III CRC patients.

Methods

Between April 2009 and April 2015, we reviewed medical records from a total of 60 stage I–III CRC patients who had peritoneal fluid collected during operation. Patients who had positive cytology in the assessment of peritoneal fluid were excluded. We evaluated the values of CEA in peritoneal fluid (pCEA) to predict the long-term outcomes of these patients using Kaplan-Meier curves and Cox regression models.

Results

The median follow-up duration was 37 months (interquartile range, 21–50 months). On receiver operating characteristic analysis, pCEA had the largest area under the curve (0.793; 95% confidence interval, 0.635–0.950; P=0.001) with an optimal cutoff value of 26.84 (sensitivity, 80.0%; specificity, 76.6%) for predicting recurrence. The recurrence rate was 8.1% in patients with low pCEA (<26.84 ng/mL, n=37), and 52.2% in patients with high pCEA (≥26.84 ng/mL, n=23). In multivariate Cox regression analysis, high pCEA (≥26.84 ng/mL) was a risk factor for poor cancer-free survival (CFS) in stage I–III patients.

Conclusions

In this study, we determined that high pCEA (≥26.84 ng/mL) detected during operation was helpful for the prediction of poor CFS in patients with stage I–III CRC.

Citations

Citations to this article as recorded by

Evaluation of peritoneal Carcinoembryonic Antigen as a survival prognostic factor in gastric cancer patients: a single western center experience
Nicola Natalizi, Elisabetta Marino, Luigina Graziosi, Annibale Donini
Updates in Surgery.2023; 75(5): 1211. CrossRef
Prognostic Significance of Preoperative Serum Carcinoembryonic Antigen Varies with Lymph Node Metastasis Status in Colorectal Cancer
Jing Jia, MinZhe Li, Wenhao Teng, Lin Wang, Weidong Zang, Jun Xiao, Ying Chen, Dan Zhao
Journal of Oncology.2021; 2021: 1. CrossRef

9,127 View
87 Download
2 Web of Science
2 Crossref

Miscellaneous

Risk factors for severity of colonic diverticular hemorrhage: Ken Kinjo, Toshiyuki Matsui, Takashi Hisabe, Hiroshi Ishihara, Toshiki Kojima, Kenta Chuman, Shigeyoshi Yasukawa, Tsuyoshi Beppu, Akihiro Koga, Satoshi Ishikawa, Masahiro Kishi, Noritaka Takatsu, Fumihito Hirai, Kenshi Yao, Toshiharu Ueki, Masakazu Washio; Intest Res 2018;16(3):458-466. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.458

Abstract PDF PubReader ePub

Background/Aims

Colonic diverticular hemorrhage (DH) was a rare disease until the 1990s, and its incidence has increased rapidly since 2000 in Japan. In recent years, colonic DH has been the most frequent cause of lower gastrointestinal bleeding (LGIB). Nearly all cases of DH are mild, with the bleeding often stopping spontaneously. Some cases, however, require surgery or arterial embolization. In this study, using a cohort at Fukuoka University Chikushi Hospital, we investigated factors associated with severe colonic DH.

Methods

Among patients with LGIB who underwent colonoscopy at our hospital between 1995 and 2013, DH was identified in 273 patients. Among them, 62 patients (22.7%) were defined as having severe colonic DH according to recurrence of bleeding in a short period, and/or the necessity of transfusion, arterial embolization, or surgery. We then evaluated risk factors for severe DH among DH patients in this retrospective cohort.

Results

Among the 273 patients with DH, use of non-steroidal anti-inflammatory drugs (NSAIDs) (odds ratio [OR], 2.801; 95% confidence interval [CI], 1.164–6.742), Charlson Risk Index (CRI) ≥2 (OR, 3.336; 95% CI, 1.154–7.353), right-sided colonic DH (OR, 3.873; 95% CI, 1.554–9.653), and symptoms of cerebral hypoperfusion (such as light-headedness, dizziness, or syncope) (OR, 2.926; 95% CI, 1.310–6.535) showed an increased risk of severe DH even after controlling for other factors.

Conclusions

Severe DH occurred in 23% of DH patients, and NSAID use, CRI ≥2, right-sided colonic DH, and symptoms of cerebral hypoperfusion are suggested to be predictors of severe DH.

Citations

Citations to this article as recorded by

Clinical Factors Associated with Severity of Colonic Diverticular Bleeding and Impact of Bleeding Site
Hirohito Amano, Takatsugu Yamamoto, Ken Ikusaka, Naoaki Aoki, Miyoko Sakurai, Taku Honda, Kyohei Maruyama, Hitoshi Aoyagi, Akari Isono, Koichiro Abe, Yoshinari Asaoka, Shinya Kodashima, Atsushi Tanaka
Journal of Clinical Medicine.2023; 12(5): 1826. CrossRef
Effectiveness and Safety of Endoscopic Submucosal Dissection for Colorectal Neoplasm in Patients with High Charlson Comorbidity Index Score: A HASID Multicenter Study
Dong-Hyun Kim, Yong-Wook Jung, Byung-Chul Jin, Hyung-Hoon Oh, Hyo-Yeop Song, Seong-Jung Kim, Dae-Seong Myung, Sang-Wook Kim, Jun Lee, Geom-Seog Seo, Young-Eun Joo, Hyun-Soo Kim
Journal of Clinical Medicine.2023; 12(19): 6255. CrossRef
Risk factors for patients hospitalized with recurrent colon diverticular bleeding: a single center experience
Hye-Su You, Dong Hyun Kim, Seo-Yeon Cho, Seon-Young Park, Chang Hwan Park, Hyun-Soo Kim, Sung Kyu Choi
Frontiers in Medicine.2023;[Epub] CrossRef
Construction of a Model for Predicting the Severity of Diverticular Bleeding in an Elderly Population
Tomoyuki Okada, Tsuyoshi Mikamo, Ayana Nakashima, Atsushi Yanagitani, Kiwamu Tanaka, Hajime Isomoto
Internal Medicine.2022; 61(15): 2247. CrossRef
Diagnosis and Treatment of Colonic Diverticular Disease
You Sun Kim
The Korean Journal of Gastroenterology.2022; 79(6): 233. CrossRef
Development and Validation of Predictive Assessment of Complicated Diverticulitis Score
Marcello Covino, Valerio Papa, Antonio Tursi, Benedetta Simeoni, Loris Riccardo Lopetuso, Lorenzo Maria Vetrone, Francesco Franceschi, Gianludovico Rapaccini, Antonio Gasbarrini, Alfredo Papa
Journal of Personalized Medicine.2021; 11(2): 80. CrossRef
Risk of Rebleeding in Patients with Small Bowel Vascular Lesions
Akira Harada, Takehiro Torisu, Shin Fujioka, Yuichiro Yoshida, Yasuharu Okamoto, Yuta Fuyuno, Atsushi Hirano, Junji Umeno, Kumiko Torisu, Tomohiko Moriyama, Motohiro Esaki, Takanari Kitazono
Internal Medicine.2021; 60(23): 3663. CrossRef
Vegetarianism as a protective factor for asymptomatic colonic diverticulosis in Asians: a retrospective cross-sectional and case-control study
Jihun Bong, Hyoun Woo Kang, Hyeki Cho, Ji Hyung Nam, Dong Kee Jang, Jae Hak Kim, Jun Kyu Lee, Yun Jeong Lim, Moon-Soo Koh, Jin Ho Lee
Intestinal Research.2020; 18(1): 121. CrossRef

9,261 View
131 Download
9 Web of Science
8 Crossref

IBD

Magnetic resonance enterography predicts the prognosis of Crohn's disease: Ji Hoon Lee, Yong Eun Park, Nieun Seo, Hyun Jung Lee, Soo Jung Park, Tae Il Kim, Won Ho Kim, Joon Seok Lim, Jae Hee Cheon; Intest Res 2018;16(3):445-457. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.445

Abstract PDF PubReader ePub

Background/Aims

Magnetic resonance enterography (MRE) has emerged as an important tool in the diagnosis and follow-up of Crohn's disease (CD). The aim of this study was to evaluate whether MRE findings could predict the prognosis of CD.

Methods

In this retrospective study, a total of 173 patients with clinical remission of CD (n=61) or active CD (n=112) were identified. The outcomes of clinical relapse, admission, surgery, and need for other medications according to the MRE findings were evaluated.

Results

The presence of active inflammation on MRE was observed in 93 (83%) patients with clinically active CD and in 44 (72.1%) patients with clinical remission of CD, without a statistically significant difference (P=0.091). In multivariate analysis, active inflammation on MRE increased the risk for clinical relapse (hazard ratio [HR], 6.985; 95% confidence interval [CI], 1.024–47.649) in patients with clinical remission of CD. In patients with clinically active CD, active inflammation on MRE increased the risk for CD-related hospitalization (HR, 2.970; 95% CI, 1.006–8.772).

Conclusions

The presence of active inflammation on MRE was significantly associated with poor prognosis both in patients with clinical remission of CD and in those with active CD.

Citations

Citations to this article as recorded by

The Spectrum of Magnetic Resonance Enterography Findings and the Role of Diffusion-Weighted Imaging in Patients with Active Crohn’s Disease
Arvin Arian, Ghazal Roostaei, Seyede Sahel Rasoulighasemlouei, Foroogh Alborzi Avanaki, Nasser Ebrahimi Daryani
Middle East Journal of Digestive Diseases.2024; 16(1): 23. CrossRef
Distribution of small bowel involvement and its association with clinical outcomes in patients with Crohn’s disease
Jin Park, Hae Young Kim, Yoon Jin Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee
Medicine.2023; 102(40): e35040. CrossRef
Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy
Kyunghwan Oh, Eun Hye Oh, Soo Min Noh, Seong Ho Park, Nayoung Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Clinical and Translational Gastroenterology.2022; 13(1): e00442. CrossRef
MR Enterography in Crohnʼs Disease: Comparison of Contrast Imaging with Diffusion-weighted Imaging and a special Form of Color Coding
Maja Jakob, Maik Backes, Christian Schaefer, Joerg Albert, Angela Geissler
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.2022; 194(10): 1119. CrossRef
Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intestinal Research.2021; 19(4): 365. CrossRef
Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn’s Disease
Eléonore Hallé, Mustapha Azahaf, Nicolas Duveau, Thomas Lambin, Maria Nachury, Julien Branche, Romain Gérard, Clémentine Lauriot Dit Prevost, Pauline Wils, Pierre Desreumaux, Olivier Ernst, Benjamin Pariente
Digestive Diseases and Sciences.2020; 65(9): 2664. CrossRef
Magnetic Resonance Enterography and Capsule Endoscopy in Patients Undergoing Patency Capsule for the Evaluation of Small Bowel Crohn’s Disease: A Korean Clinical Experience
Hyun Seok Lee, Yun Jeong Lim, Jin-Hee Jung, Ji Hyung Nam, Junseok Park, Sun Hyung Kang, Ki Bae Kim, Hoon Jai Chun
Gastroenterology Research and Practice.2020; 2020: 1. CrossRef
Beyond Crohn Disease
Michael S. Furman, Edward Y. Lee
Radiologic Clinics of North America.2020; 58(3): 517. CrossRef
Mucosal healing in Crohn’s disease: new insights
Salvatore Cucchiara, Giulia D’Arcangelo, Sara Isoldi, Marina Aloi, Laura Stronati
Expert Review of Gastroenterology & Hepatology.2020; 14(5): 335. CrossRef
Changes in the Management of Patients with Crohn’s Disease Based on Magnetic Resonance Enterography Patterns
Evelyn Sayuri S. Chinem, Barbara C. Esberard, Andre da L. Moreira, Tatiana G. Barbassa, Guilherme M. da Cunha, Antonio Jose de V. Carneiro, Heitor S. de Souza, Ana Teresa P. Carvalho
Gastroenterology Research and Practice.2019; 2019: 1. CrossRef

7,222 View
105 Download
9 Web of Science
10 Crossref

IBD

What nutritional factors influence bone mineral density in Crohn's disease patients?: Fernanda Gomes Coqueiro, Raquel Rocha, Camilla Almeida Menezes, Mirella Brasil Lopes, Vanessa Rosa Oliveira, Flora Maria Lorenzo Fortes, Genoile Oliveira Santana; Intest Res 2018;16(3):436-444. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.436

Abstract PDF PubReader ePub

Background/Aims

Bone mineral density (BMD) is often low in patients with Crohn's disease (CD). This study aimed to evaluate the association between nutritional factors and BMD in a group of CD patients.

Methods

CD patients 18 years of age or older were included. The body mass index (BMI), waist circumference (WC) and dietary intake were evaluated during two 24-hour recalls. Bone densitometry was performed by dual-energy X-ray absorptiometry of the full body to assess body composition and of the lumbar vertebrae and femoral neck to assess BMD.

Results

In the 60 patients evaluated, there was no association between BMD and disease activity or between BMD and disease duration. We observed moderate correlations between BMD in at least one of the evaluated sites and BMI, lean mass, WC, and protein, calcium, phosphorus and magnesium dietary intakes (P<0.05). In the linear regression analysis for spinal BMD, only BMI and calcium dietary intake remained associated (P<0.05). In the linear regression analysis for femoral BMD, WC and phosphorus intake continued to be significant in the final model, although they had low explanatory power for BMD (P<0.05).

Conclusions

The prevalence of low BMD was high in CD patients. BMI, WC, calcium and phosphorus dietary intake were positively correlated with BMD.

Citations

Citations to this article as recorded by

The Effect of Protein Nutritional Support on Inflammatory Bowel Disease and Its Potential Mechanisms
Qingye Li, Jing Wang
Nutrients.2024; 16(14): 2302. CrossRef
Assessment of dietary nutrient intake and its relationship to the nutritional status of patients with Crohn’s Disease in Guangdong Province of China
Hong Zheng, Xinbin Chen, Xiaoling Bu, Xia Qiu, Demeng Zhang, Yitong Zhou, Junlong Lin, Jinghong Li, Wenjun Ma, Ying Zheng
Nutrición Hospitalaria.2023;[Epub] CrossRef
Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease
Natsuki Ishida, Tomohiro Higuchi, Takahiro Miyazu, Satoshi Tamura, Satoshi Suzuki, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto, Mathilde Body-Malapel
PLOS ONE.2021; 16(4): e0250658. CrossRef
Osteoporosis Complications in Crohn's Disease Patients: Factors, Pathogenesis, and Treatment Outlines
Yaqot N Baban, Christopher M Edicheria, Joseph Joseph, Parneet Kaur, Jihan A Mostafa
Cureus.2021;[Epub] CrossRef
Crohn Disease and Fracture Risk Assessment With FRAX
Grethe B Jonasson, Jack Hilon, Bengt Hasseus, Torgny Alstad, Hossein Kashani
Crohn's & Colitis 360.2019;[Epub] CrossRef

6,284 View
72 Download
5 Web of Science
5 Crossref

IBD

Selective M1 macrophage polarization in granuloma-positive and granuloma-negative Crohn's disease, in comparison to intestinal tuberculosis: Prasenjit Das, Ritika Rampal, Sonakshi Udinia, Tarun Kumar, Sucharita Pilli, Nahid Wari, Imtiaz Khan Ahmed, Saurabh Kedia, Siddhartha Datta Gupta, Dhiraj Kumar, Vineet Ahuja; Intest Res 2018;16(3):426-435. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.426

Abstract PDF PubReader ePub

Background/Aims

Classical M1 macrophage activation exhibits an inflammatory phenotype while alternative M2 macrophage activation exhibits an anti-inflammatory phenotype. We aimed to determine whether there are discriminant patterns of macrophage polarization in Crohn's disease (CD) and intestinal tuberculosis (iTB).

Methods

Colonic mucosal biopsies from 29 patients with iTB, 50 with CD, and 19 controls were examined. Dual colored immunohistochemistry was performed for iNOS/CD68 (an M1_φ marker) and CD163/CD68 (an M2_φ marker), and the ratio of M1_φ to M2_φ was assessed. To establish the innate nature of macrophage polarization, we analyzed the extent of mitochondrial depolarization, a key marker of inflammatory responses, in monocyte-derived macrophages obtained from CD and iTB patients, following interferon-γ treatment.

Results

M1_φ polarization was more prominent in CD biopsies (P=0.002) than in iTB (P=0.2) and control biopsies. In granuloma-positive biopsies, including those in CD, M1_φ predominance was significant (P=0.001). In iTB, the densities of M1_φ did not differ between granuloma-positive and granuloma-negative biopsies (P=0.1). Interestingly, higher M1_φ polarization in CD biopsies correlated with high inflammatory response exhibited by peripheral blood-derived monocytes from these patients.

Conclusions

Proinflammatory M1_φ polarization was more common in colonic mucosa of CD patients, especially in the presence of mucosal granulomas. Further characterization of the innate immune system could help in clarifying the pathology of iTB and CD.

Citations

Citations to this article as recorded by

Macrophage polarization: an important role in inflammatory diseases
Min Luo, Fukun Zhao, Huan Cheng, Mu Su, Yuanmin Wang
Frontiers in Immunology.2024;[Epub] CrossRef
The gut barrier as a gatekeeper in colorectal cancer treatment
Roy Hajjar, Carole Richard, Manuela M. Santos
Oncotarget.2024; 15(1): 562. CrossRef
New diagnostic strategies to distinguish Crohn's disease and gastrointestinal tuberculosis
Himanshu Narang, Saurabh Kedia, Vineet Ahuja
Current Opinion in Infectious Diseases.2024; 37(5): 392. CrossRef
Differentiating gastrointestinal tuberculosis and Crohn's disease- a comprehensive review
Arup Choudhury, Jasdeep Dhillon, Aravind Sekar, Pankaj Gupta, Harjeet Singh, Vishal Sharma
BMC Gastroenterology.2023;[Epub] CrossRef
Clinical Usefulness of Immune Profiling for Differential Diagnosis between Crohn’s Disease, Intestinal Tuberculosis, and Behcet’s Disease
Ji Won Yoo, Su In Jo, Dong Woo Shin, Ji Won Park, Sung-Eun Kim, Hyun Lim, Ho Suk Kang, Sung-Hoon Moon, Min Kyu Kim, Sang-Yeob Kim, Sung Wook Hwang, Jae Seung Soh
Diagnostics.2023; 13(18): 2904. CrossRef
Production of granulomas in Mycoplasma bovis infection associated with meningitis-meningoencephalitis, endocarditis, and pneumonia in cattle
Mathurot Suwanruengsri, Ryoko Uemura, Takuya Kanda, Naoyuki Fuke, Phawut Nueangphuet, Apisit Pornthummawat, Masahiro Yasuda, Takuya Hirai, Ryoji Yamaguchi
Journal of Veterinary Diagnostic Investigation.2022; 34(1): 68. CrossRef
Human M1 macrophages express unique innate immune response genes after mycobacterial infection to defend against tuberculosis
Arshad Khan, Kangling Zhang, Vipul K. Singh, Abhishek Mishra, Priyanka Kachroo, Tian Bing, Jong Hak Won, Arunmani Mani, Ramesha Papanna, Lovepreet K. Mann, Eder Ledezma-Campos, Genesis Aguillon-Duran, David H. Canaday, Sunil A. David, Blanca I. Restrepo,
Communications Biology.2022;[Epub] CrossRef
Lacticaseibacillus casei Strain Shirota Modulates Macrophage-Intestinal Epithelial Cell Co-Culture Barrier Integrity, Bacterial Sensing and Inflammatory Cytokines
Andrew Foey, Neama Habil, Alex Strachan, Jane Beal
Microorganisms.2022; 10(10): 2087. CrossRef
Biomaterial-based osteoimmunomodulatory strategies via the TLR4-NF-κB signaling pathway: A review
Haiyuan Xing, Ruiyan Li, Yun'an Qing, Boda Ying, Yanguo Qin
Applied Materials Today.2021; 22: 100969. CrossRef
Two ST11 Klebsiella pneumoniae strains exacerbate colorectal tumorigenesis in a colitis-associated mouse model
Ming-Ko Chiang, Pei-Yi Hsiao, Yen-Yi Liu, Hui-Ling Tang, Chien-Shun Chiou, Min-Chi Lu, Yi-Chyi Lai
Gut Microbes.2021;[Epub] CrossRef
A combination of circulating microRNA-375-3p and chemokines CCL11, CXCL12, and G-CSF differentiate Crohn’s disease and intestinal tuberculosis
Susree Roy, Suchandrima Ghosh, Mallica Banerjee, Sayantan Laha, Dipanjan Bhattacharjee, Rajib Sarkar, Sujay Ray, Arko Banerjee, Ranajoy Ghosh, Aniket Halder, Alakendu Ghosh, Raghunath Chatterjee, Simanti Datta, Gopal Krishna Dhali, Soma Banerjee
Scientific Reports.2021;[Epub] CrossRef
Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization
Xiao Liu, Yan Su, Xueyan Sun, Haixia Fu, Qiusha Huang, Qi Chen, Xiaodong Mo, Meng Lv, Yuan Kong, Lanping Xu, Xiaojun Huang, Xiaohui Zhang
Science China Life Sciences.2020; 63(11): 1744. CrossRef
Heterogeneous macrophages: Supersensors of exogenous inducing factors
Caiyun Qian, Zehui Yun, Yudi Yao, Minghua Cao, Qiang Liu, Song Hu, Shuhua Zhang, Daya Luo
Scandinavian Journal of Immunology.2019;[Epub] CrossRef
Understanding Pathogenesis and Care Challenges of Immune Reconstitution Inflammatory Syndrome in Fungal Infections
Sarah Dellière, Romain Guery, Sophie Candon, Blandine Rammaert, Claire Aguilar, Fanny Lanternier, Lucienne Chatenoud, Olivier Lortholary
Journal of Fungi.2018; 4(4): 139. CrossRef

11,592 View
134 Download
14 Web of Science
14 Crossref

IBD

The incidence and risk factors of venous thromboembolism in Japanese inpatients with inflammatory bowel disease: a retrospective cohort study: Katsuyoshi Ando, Mikihiro Fujiya, Yoshiki Nomura, Yuhei Inaba, Yuuya Sugiyama, Takuya Iwama, Masami Ijiri, Keitaro Takahashi, Kazuyuki Tanaka, Aki Sakatani, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Yusuke Mizukami, Toshikatsu Okumura; Intest Res 2018;16(3):416-425. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.416

Abstract PDF PubReader ePub

Background/Aims

Venous thromboembolism (VTE) is a major extraintestinal manifestation in inflammatory bowel disease (IBD), regarded as an independent risk factor for VTE according to reports from Western countries. However, the incidence and risk factors of VTE in Asian IBD patients are not fully understood. We aimed to reveal the incidence and risk factors of VTE in Japanese IBD inpatients.

Methods

The incidence of VTE in inpatients with IBD (n=340), gastrointestinal cancers (n=557), and other gastrointestinal diseases (n=569) treated at our hospital from 2009 to 2013 was retrospectively investigated. The characteristics and laboratory data of IBD inpatients with and without VTE were compared in univariate and multivariate analyses. Clinical courses of VTE in IBD were surveyed.

Results

VTE was detected in 7.1% of IBD inpatients, significantly higher than in gastrointestinal cancer inpatients (2.5%) and inpatients with other gastrointestinal diseases (0.88%). The incidence of VTE in ulcerative colitis (UC) patients (16.7%) was much higher than that in those with Crohn's disease (3.6%). In the univariate analysis, the risk factors were an older age, central venous catheter, prednisolone, surgery, low serum albumin, high serum C-reactive protein and D-dimer. According to a multivariate analysis, >50 years of age and surgery were the only risk factors. The in-hospital mortality rate of IBD inpatients with VTE was 4.2%.

Conclusions

The incidence of VTE with IBD, especially UC, was found to be high compared with other digestive disease, which was almost equivalent to that of Western countries. The efficacy of prophylaxis needs to be investigated in Asian IBD patients.

Citations

Citations to this article as recorded by

Anti-tumor Necrosis Factor Alpha Versus Corticosteroids: A 3-fold Difference in the Occurrence of Venous Thromboembolism in Inflammatory Bowel Disease－A Systematic Review and Meta-analysis
Hajnal Székely, Laura Mária Tóth, Anett Rancz, Anna Walter, Nelli Farkas, Miklós Domonkos Sárközi, Szilárd Váncsa, Bálint Erőss, Péter Hegyi, Pál Miheller
Journal of Crohn's and Colitis.2024; 18(5): 773. CrossRef
Extended Post Discharge Prophylaxis for Venous Thromboembolism Prevention After Bariatric Surgery
Francisco A. Guzman-Pruneda, Ambar Garcia, Robert W. Crum, Theresa Chen, Abraham Krikhely, Marc Bessler
Obesity Surgery.2024; 34(4): 1217. CrossRef
Predictive Value of Serum Inflammatory Markers on Activity of Ulcerative Colitis
小梅马
Advances in Clinical Medicine.2024; 14(02): 4453. CrossRef
Fibrinogen, FDP and D-Dimer as Potential Biomarkers for Disease Severity in Ulcerative Colitis: A Retrospective Study
Wan Feng, Lei Zhu, Song Zhao, Kai Zheng, Luzhou Xu, Hong Shen
International Journal of General Medicine.2024; Volume 17: 5573. CrossRef
The Journey Through the Pathogenesis and Treatment of Venous Thromboembolism in Inflammatory Bowel Diseases: A Narrative Review
Andrea Boccatonda, Marco Balletta, Susanna Vicari, Ariela Hoxha, Paolo Simioni, Elena Campello
Seminars in Thrombosis and Hemostasis.2023; 49(07): 744. CrossRef
Risk of venous thromboembolism with a central venous catheter in hospitalized Japanese patients with inflammatory bowel disease: a propensity score-matched cohort study
Yasuhiro Aoki, Hiroki Kiyohara, Yohei Mikami, Kosaku Nanki, Takaaki Kawaguchi, Yusuke Yoshimatsu, Shinya Sugimoto, Tomohisa Sujino, Kaoru Takabayashi, Naoki Hosoe, Haruhiko Ogata, Yasushi Iwao, Takanori Kanai
Intestinal Research.2023; 21(3): 318. CrossRef
Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review
Maria Puig, Helena Masnou, Francisco Mesonero, Luís Menchén, Luís Bujanda, Jesús Castro, Irene González-Partida, Raquel Vicente, Carlos González-Muñoza, Marisa Iborra, Mónica Sierra, José María Huguet, María José García, Ruth De Francisco, Francisco Javie
Journal of Clinical Medicine.2023; 12(23): 7366. CrossRef
Preoperative prevalence and risk factors of deep-vein thrombosis in Japanese surgical patients with ulcerative colitis: a retrospective investigational study
Hiroki Ohya, Hideaki Kimura, Jun Watanabe, Kazuya Nakagawa, Yusuke Suwa, Mayumi Ozawa, Atsushi Ishibe, Reiko Kunisaki, Chikara Kunisaki, Itaru Endo
Surgery Today.2022; 52(2): 251. CrossRef
Real-World Insurance Claims Analysis of Venous Thromboembolism in Japanese Patients with Inflammatory Bowel Disease
Mikihiro Fujiya, Tsutomu Kawaguchi, Shoko Arai, Naoki Isogawa, Shintaro Hiro, Fumihiro Matsumoto, Satoshi Yamaguchi, Noritoshi Yoshii, Mashio Nakamura, Katsuyoshi Matsuoka
Digestive Diseases and Sciences.2022; 67(11): 5195. CrossRef
Venous thromboembolism in chronic gastrointestinal disorders
Federica Melazzini, Francesca Calabretta, Marco Vincenzo Lenti, Antonio Di Sabatino
Expert Review of Gastroenterology & Hepatology.2022; 16(5): 437. CrossRef
Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease: A Two-year Retrospective Study of Patients Presenting With Inflammatory Bowel Disease to a Community Hospital
Dominic Amakye, Onoriode Kesiena, Ademayowa Ademiluyi, Margaret Gavor, Zahraa Rabeeah
Cureus.2022;[Epub] CrossRef
Thromboembolism is associated with poor prognosis and high mortality in patients with inflammatory bowel disease: A case–control study
Yadukrishna S., Saurabh Kedia, Varun Teja, Sudheer Kumar Vuyyuru, Nidhi Yadav, Pabitra Sahu, Saransh Jain, Dawesh P. Yadav, Sawan Bopanna, Venigalla Pratap Mouli, Deepak Madhu, Raju Sharma, Prasenjit Das, Govind Makharia, Vineet Ahuja
Indian Journal of Gastroenterology.2022;[Epub] CrossRef
Venous thromboembolism in pediatric inflammatory bowel disease: an 11-year population-based nested case–control study in Canada
Zhaolu Ding, Mary Sherlock, Anthony K.C. Chan, Mary Zachos
Blood Coagulation & Fibrinolysis.2022; 33(8): 449. CrossRef
Risk of venous thromboembolism in Asian patients with inflammatory bowel disease: a nationwide cohort study
Chan Mi Heo, Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Mi Yang, Seonwoo Kim, Young-Ho Kim
Scientific Reports.2021;[Epub] CrossRef
Probiotic-Derived Polyphosphate Accelerates Intestinal Epithelia Wound Healing through Inducing Platelet-Derived Mediators
Shotaro Isozaki, Hiroaki Konishi, Mikihiro Fujiya, Hiroki Tanaka, Yuki Murakami, Shin Kashima, Katsuyoshi Ando, Nobuhiro Ueno, Kentaro Moriichi, Toshikatsu Okumura, Hirokazu Fukui
Mediators of Inflammation.2021; 2021: 1. CrossRef
Risk Factors of Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Hua Zhang, Xuehong Wang
Frontiers in Medicine.2021;[Epub] CrossRef
Perioperative Venous Thromboembolism in Ulcerative Colitis: A Multicenter Prospective Study in Japan
Michio Itabashi, Hiroki Ikeuchi, Hideaki Kimura, Kohei Fukushima, Hisao Fujii, Riichiro Nezu, Kitaro Futami, Akira Sugita, Yasuo Suzuki, Tadakazu Hisamatsu
Crohn's & Colitis 360.2021;[Epub] CrossRef
Incidence and risk factors for venous thrombosis among patients with inflammatory bowel disease in China: a multicenter retrospective study
Jing Liu, Xiang Gao, Ye Chen, Qiao Mei, Liangru Zhu, Jiaming Qian, Pinjin Hu, Qian Cao
Intestinal Research.2021; 19(3): 313. CrossRef
A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan
Katsuyoshi Ando, Mikihiro Fujiya, Kenji Watanabe, Sakiko Hiraoka, Hisashi Shiga, Shinji Tanaka, Hideki Iijima, Tsunekazu Mizushima, Taku Kobayashi, Masakazu Nagahori, Hiroki Ikeuchi, Shingo Kato, Takehiro Torisu, Kiyonori Kobayashi, Masaaki Higashiyama, T
Journal of Gastroenterology.2021; 56(12): 1062. CrossRef
Prevalence of Asymptomatic Venous Thromboembolism in Depressive Inpatients

Masahiro Takeshima, Hiroyasu Ishikawa, Yoshiaki Umeta, Mizuki Kudoh, Akise Umakoshi, Kazuhisa Yoshizawa, Yu Ito, Tomoko Hosoya, Ko Tsutsui, Hidenobu Ohta, Kazuo Mishima
Neuropsychiatric Disease and Treatment.2020; Volume 16: 579. CrossRef
Venous thromboembolism in inflammatory bowel disease
Kimberly Cheng, Adam S Faye
World Journal of Gastroenterology.2020; 26(12): 1231. CrossRef
Inflammatory Bowel Disease Therapy and Venous Thromboembolism
Thomas Lambin, Adam S. Faye, Jean-Frédéric Colombel
Current Treatment Options in Gastroenterology.2020; 18(3): 462. CrossRef
Clinical Case of Complicated Thrombophilia in a Patient with Ulcerative Colitis
S. A. Boldueva, I. V. Yarmosh, A. N. Dolinova, Z. G. Kaloeva, M. Yu. Serkova, V. M. Avramova
Rational Pharmacotherapy in Cardiology.2020; 16(5): 737. CrossRef
Letter: different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases
Ru Ding, Jianjiang Xu, Zhiqing He, Yihong Chen, Anna Hultgårdh‐Nilsson, Chun Liang
Alimentary Pharmacology & Therapeutics.2019; 49(3): 345. CrossRef
Mechanical Thrombectomy as an Initial Treatment for Sinus Thrombosis
Yusuke Takahashi, Yoshitaka Suda, Ayana Saito, Ryosei Wakasa
Journal of Neuroendovascular Therapy.2019; 13(12): 507. CrossRef
Ein Infekt unklarer Genese
Constanze H. Waggershauser
Gastro-News.2018; 5(5): 6. CrossRef

7,863 View
195 Download
23 Web of Science
26 Crossref

IBD

The association between new generation oral contraceptive pill and the development of inflammatory bowel diseases: Santosh Sanagapalli, Yanna Ko, Viraj Kariyawasam, Siew C Ng, Whitney Tang, Hithanadura Janaka de Silva, Minhu Chen, Kaichun Wu, Satimai Aniwan, Ka Kei Ng, David Ong, Qin Ouyang, Ida Hilmi, Marcellus Simadibrata, Pises Pisespongsa, Saranya Gopikrishna, Rupert W Leong; Intest Res 2018;16(3):409-415. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.409

Abstract PDF PubReader ePub

Background/Aims

To examine the association between use of oral contraceptive pills (OCPs) and the risk of developing inflammatory bowel diseases (IBD), in a modern cohort.

Methods

A prospective nested case-control study across sites in the Asia-Pacific region was conducted; involving female IBD cases and asymptomatic controls. Subjects completed a questionnaire addressing questions related to OCP use. Primary outcome was the risk of development of IBD of those exposed to OCP versus non-exposure. Secondary outcomes were development of Crohn's disease (CD) versus ulcerative colitis (UC), and whether age of first use of OCP use may be associated with risk of IBD.

Results

Three hundred and forty-eight female IBD cases (41% CD, median age: 43 years) and 590 female age-matched controls were recruited. No significant association was found between OCP use and the risk of IBD (odds ratio [OR], 1.65; 95% confidence interval, 0.77–3.13; P=0.22), CD (OR, 1.55) or UC (OR, 1.01). The lack of association persisted when results were adjusted for age and smoking. IBD cases commenced OCP use at a younger age than controls (18 years vs. 20 years, P=0.049).

Conclusions

In this large cohort of subjects from the Asia-Pacific region, we found a modest but not significantly increased risk of developing IBD amongst OCP users.

Citations

Citations to this article as recorded by

Estrogen receptor actions in colitis
Erika L. Garcia-Villatoro, Clinton D. Allred
Essays in Biochemistry.2021; 65(6): 1003. CrossRef
Sex-based differences in inflammatory bowel diseases: a review
Sheila D. Rustgi, Maia Kayal, Shailja C. Shah
Therapeutic Advances in Gastroenterology.2020;[Epub] CrossRef

7,534 View
104 Download
4 Web of Science
2 Crossref

IBD

Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease: Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang; Intest Res 2018;16(3):400-408. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.400

Abstract PDF PubReader ePub

Background/Aims

This study aimed to elucidate the prevalence of hepatitis B virus (HBV) serologic markers in Korean patients newly diagnosed with, but not yet treated for inflammatory bowel disease (IBD).

Methods

We prospectively enrolled 210 patients newly diagnosed with IBD (109 with ulcerative colitis and 101 with Crohn's disease). Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) levels were measured and compared with those of 1,100 sex- and age-matched controls.

Results

The prevalence of chronic HBV infection (positive HBsAg, positive anti-HBc, and negative anti-HBs results) and past infection (negative HBsAg, positive anti-HBc, and positive or negative anti-HBs results) were not significantly different between the patients and controls (chronic HBV infection: IBD, 3.8% vs. control, 4.9%, P=0.596; past infection: IBD, 26.2% vs. control, 28.8%, P=0.625). The patients with IBD aged <20 years were at a higher susceptibility risk (nonimmune) for HBV infection than the controls (IBD, 41.5% vs. control, 22.4%; P=0.018). In the multivariate analysis, an age of <20 years (P=0.024) and symptom duration of ≥12 months before diagnosis (P=0.027) were identified as independent risk factors for nonimmunity against HBV infection.

Conclusions

The patients newly diagnosed with IBD were susceptible to HBV infection. The frequency of nonimmunity was high, especially in the patients aged <20 years and those with a longer duration of symptoms before diagnosis. Therefore, it is necessary to screen for HBV serologic markers and generate a detailed vaccination plan for patients newly diagnosed with IBD.

Citations

Citations to this article as recorded by

Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis
Suprabhat Giri, Dhiraj Agrawal, Shivaraj Afzalpurkar, Sunil Kasturi, Amrit Gopan, Sridhar Sundaram, Aditya Kale
Intestinal Research.2023; 21(3): 392. CrossRef
Viral Hepatitis in Patients with Inflammatory Bowel Disease
Seung Hwan Shin, Sang Hyoung Park
The Korean Journal of Gastroenterology.2022; 80(2): 51. CrossRef
Vaccination strategies for Korean patients with inflammatory bowel disease
Yoo Jin Lee, Eun Soo Kim
The Korean Journal of Internal Medicine.2022; 37(5): 920. CrossRef
Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment
Georgios Axiaris, Evanthia Zampeli, Spyridon Michopoulos, Giorgos Bamias
World Journal of Gastroenterology.2021; 27(25): 3762. CrossRef
Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases
Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, Heeyoung Lee, Eun Sun Kim, Jae Jun Park, Chan Hyuk Park, Bo-In Lee, Yunho Jung, Dong-Il Park, Do Young Kim, Hana Park, Yoon Tae Jeen
Intestinal Research.2020; 18(1): 18. CrossRef
Evaluating Hepatitis B Seroprotection and Revaccination for Children With Inflammatory Bowel Disease
Erica J Brenner, Ravi Jhaveri, Michael D Kappelman, Ajay S Gulati
Inflammatory Bowel Diseases.2019; 25(9): e108. CrossRef
The importance of immunization in immune-mediated inflammatory disease cannot be overstated
Sang Hyoung Park
Intestinal Research.2018; 16(3): 325. CrossRef

7,168 View
99 Download
7 Web of Science
7 Crossref

IBD

Immunohistochemical differentiation between chronic enteropathy associated with SLCO2A1 gene and other inflammatory bowel diseases: Satoko Yamaguchi, Shunichi Yanai, Shotaro Nakamura, Keisuke Kawasaki, Makoto Eizuka, Noriyuki Uesugi, Tamotsu Sugai, Junji Umeno, Motohiro Esaki, Takayuki Matsumoto; Intest Res 2018;16(3):393-399. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.393

Abstract PDF PubReader ePub

Background/Aims

We recently identified recessive mutations in the solute carrier organic anion transporter family member 2A1 gene (SLCO2A1) as causative variants of chronic enteropathy associated with SLCO2A1 (CEAS). The aim of this study was to evaluate SLCO2A1 protein expression in the intestinal tissues of patients with CEAS, intestinal Behçet's disease (BD), simple ulcer (SU), and Crohn's disease (CD).

Methods

Immunohistochemical staining using a polyclonal anti-SLCO2A1 antibody was performed on the resected intestinal specimens from 13 cases of CD, 9 cases of intestinal BD/SU, and 3 cases of CEAS. The extent of SLCO2A1 expression was determined by counting positively-staining vascular endothelial cells and scored as 0 (no cells), 1 (1%–30% cells), 2 (31%–60%), or 3 (>60%). The intensity of SLCO2A1 expression was scored either as 0 (negative), 1 (intermediate), or 2 (strong). The extent score and intensity score were summed for the final score of 0, 2, 3, 4, or 5.

Results

SLCO2A1 protein expression was observed in 1 of 3 cases of CEAS (33%), all 13 cases of CD (100%), and all 9 cases of BD/SU (100%). The mean final expression scores of CEAS, CD, and BD/SU were 1.6 (range, 0–5), 4.8 (range, 4–5), and 4.3 (range, 4–5), respectively. The final expression score in CEAS was significantly lower than in CD (P=0.03).

Conclusions

Immunohistochemical staining of the SLCO2A1 protein is considered useful to distinguish CEAS from other inflammatory bowel diseases.

Citations

Citations to this article as recorded by

First case report of dichorionic diamniotic twins with chronic enteropathy associated with the SLCO2A1 gene
Ryutaro Saura, Shin-ichiro Hagiwara, Keinosuke Hizuka, Nobuhiko Okamoto, Yuri Etani
Clinical Journal of Gastroenterology.2024; 17(2): 240. CrossRef
Characteristics of chronic enteropathy associated with SLCO2A1 gene (CEAS) in children, a unique type of monogenic very early-onset inflammatory bowel disease
Jin Gyu Lim, Jae Sung Ko, Jung Min Ko, Hyun Young Kim, Man Jin Kim, Moon Woo Seong, Young Hun Choi, Gyeong Hoon Kang, Jaemoon Koh, Jin Soo Moon
BMC Pediatrics.2024;[Epub] CrossRef
Clinical and genetic characteristics of Chinese patients diagnosed with chronic enteropathy associated with SLCO2A1 gene
Qing Shang, Yimin Dai, Jingyi Huang, Wei Liu, Weixun Zhou, Yaping Liu, Hong Yang, Qiang Wang, Yue Li
Orphanet Journal of Rare Diseases.2024;[Epub] CrossRef
Histopathology underlying environmental enteric dysfunction in a cohort study of undernourished children in Bangladesh, Pakistan, and Zambia compared with United States children
Paul Kelly, Kelley VanBuskirk, David Coomes, Samer Mouksassi, Gerald Smith, Zehra Jamil, Md Shabab Hossain, Sana Syed, Chelsea Marie, Phillip I Tarr, Peter B Sullivan, William A Petri, Donna M Denno, Tahmeed Ahmed, Mustafa Mahfuz, S Asad Ali, Sean R Moore
The American Journal of Clinical Nutrition.2024; 120: S15. CrossRef
Capsule Endoscopy for the Diagnosis of Suspected Small Bowel Bleeding
P. P. Polyakov, A. Ya. Alimetov, A. V. Onopriev, A. V. Avakimyan, A. Kh. Kade, S. A. Zanin, E. S. Zanina, Z. S. Popov, A. I. Trofimenko, Z. T. Jndoyan, A. A. Avagimyan
Innovative Medicine of Kuban.2023; (3): 121. CrossRef
Attenuated Expression of SLCO2A1 Caused by DNA Methylation in Pediatric Inflammatory Bowel Disease
Natsuki Ito, Takahiro Kudo, Hidetaka Eguchi, Keisuke Jimbo, Atsushi Furuhata, Toshiaki Okuno, Ichiro Takeuchi, Katsuhiro Arai, Takashi Ishige, Yasushi Okazaki, Toshiaki Shimizu
Inflammatory Bowel Diseases.2023; 29(12): 1920. CrossRef
Updates on the diagnosis and management of cryptogenic multifocal ulcerative stenosing enteropathy (CMUSE) and non-steroidal enteropathy
Tom G. Moreels, Ayaskanta Singh
Best Practice & Research Clinical Gastroenterology.2023; 64-65: 101847. CrossRef
Chronic Enteropathy Associated with Solute Carrier Organic Anion Transporter Family, Member 2A1 (SLCO2A1) with Positive Immunohistochemistry for SLCO2A1 Protein
Chizuru Ariake, Naoki Hosoe, Hinako Sakurai, Anna Tojo, Yukie Hayashi, Kenji JL Limpias Kamiya, Tomohisa Sujino, Kaoru Takabayashi, Kenjiro Kosaki, Satowa Seki, Tadakazu Hisamatsu, Haruhiko Ogata, Takanori Kanai
Internal Medicine.2022; 61(17): 2607. CrossRef
Epithelial Abnormalities in the Small Intestine of Zambian Children With Stunting
Chola Mulenga, Sanja Sviben, Kanta Chandwe, Beatrice Amadi, Violet Kayamba, James A. J. Fitzpatrick, Victor Mudenda, Paul Kelly
Frontiers in Medicine.2022;[Epub] CrossRef
Functional analysis of mutant SLCO2A1 transporters found in patients with chronic enteropathy associated with SLCO2A1
Satowa Seki, Gen Tanaka, Toru Kimura, Mari Hayashida, Jun Miyoshi, Minoru Matsuura, Hiroyuki Sakurai, Tadakazu Hisamatsu
Journal of Gastroenterology and Hepatology.2022; 37(9): 1776. CrossRef
Clinical and Genetic Characteristics of Korean Patients Diagnosed with Chronic Enteropathy Associated with SLCO2A1 Gene: A KASID Multicenter Study
Hee Seung Hong, Jiwon Baek, Jae Chul Park, Ho-Su Lee, Dohoon Park, A-Ran Yoon, Soo Jung Park, Sung Noh Hong, Seong-Joon Koh, Chang Kyun Lee, Bo-In Lee, Sung Wook Hwang, Sang Hyoung Park, Seung-Jae Myung, Suk-Kyun Yang, Kyuyoung Song, Byong Duk Ye
Gut and Liver.2022; 16(6): 942. CrossRef
Recent advances in studies of SLCO2A1 as a key regulator of the delivery of prostaglandins to their sites of action
Takeo Nakanishi, Yoshinobu Nakamura, Junji Umeno
Pharmacology & Therapeutics.2021; 223: 107803. CrossRef
Meta-Analysis-Assisted Detection of Gravity-Sensitive Genes in Human Vascular Endothelial Cells
Yin Liang, Mengxue Wang, Yun Liu, Chen Wang, Ken Takahashi, Keiji Naruse
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Chronic Nonspecific Multiple Ulcers of the Small Intestine / Chronic Enteropathy Associated with SLCO2A1 Gene (CEAS)
Junji Umeno, Yuta Fuyuno, Yuichi Matsuno, Takehiro Torisu
Nippon Daicho Komonbyo Gakkai Zasshi.2021; 74(10): 581. CrossRef
Retrospective study of the differential diagnosis between cryptogenic multifocal ulcerous stenosing enteritis and small bowel Crohn’s disease
Dan Chen, Wei Liu, Weixun Zhou, Weiyang Zheng, Dong Wu, Jiaming Qian
BMC Gastroenterology.2020;[Epub] CrossRef
Chronic Enteropathy Associated with SLCO2A1 with Pachydermoperiostosis
Yoshikazu Tsuzuki, Ryutaro Aoyagi, Kazuya Miyaguchi, Keigo Ashitani, Hideki Ohgo, Minoru Yamaoka, Keisuke Ishizawa, Hidekazu Kayano, Tadakazu Hisamatsu, Junji Umeno, Naoki Hosoe, Takayuki Matsumoto, Hidetomo Nakamoto, Hiroyuki Imaeda
Internal Medicine.2020; 59(24): 3147. CrossRef
Small bowel ulcers
Martin Keuchel, Niehls Kurniawan, Peter Baltes
Current Opinion in Gastroenterology.2019; 35(3): 213. CrossRef
Measurement of prostaglandin metabolites is useful in diagnosis of small bowel ulcerations
Yuichi Matsuno, Junji Umeno, Motohiro Esaki, Yoichiro Hirakawa, Yuta Fuyuno, Yasuharu Okamoto, Atsushi Hirano, Shigeyoshi Yasukawa, Fumihito Hirai, Toshiyuki Matsui, Shuhei Hosomi, Kenji Watanabe, Naoki Hosoe, Haruhiko Ogata, Tadakazu Hisamatsu, Shunichi
World Journal of Gastroenterology.2019; 25(14): 1753. CrossRef
Distinction between Chronic Enteropathy Associated with the SLCO2A1 Gene and Crohn's Disease
Shunichi Yanai, Satoko Yamaguchi, Shotaro Nakamura, Keisuke Kawasaki, Yosuke Toya, Noriyuki Yamada, Makoto Eizuka, Noriyuki Uesugi, Junji Umeno, Motohiro Esaki, Eiko Okimoto, Shunji Ishihara, Tamotsu Sugai, Takayuki Matsumoto
Gut and Liver.2019; 13(1): 62. CrossRef
Chronic enteropathy associated with SLCO2A1 gene: A case report and literature review
Peng Hu, Huiqin He, Ning Dai, Shizheng Zhang, Liping Deng
Clinics and Research in Hepatology and Gastroenterology.2019; 43(5): e68. CrossRef

7,149 View
118 Download
17 Web of Science
20 Crossref

IBD

β-(1,3)-Glucan derived from Candida albicans induces inflammatory cytokines from macrophages and lamina propria mononuclear cells derived from patients with Crohn's disease: Kiyoto Mori, Makoto Naganuma, Shinta Mizuno, Hiroaki Suzuki, Mina T. Kitazume, Katsuyoshi Shimamura, Sayako Chiba, Akira Sugita, Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Takanori Kanai; Intest Res 2018;16(3):384-392. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.384

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Recent research has highlighted the importance of interactions between commensal fungi and intestinal inflammation. However, there are few studies investigating whether commensal fungi contribute to inflammation in patients with Crohn's disease (CD). The aim of this study is to investigate reveal interactions between commensal fungi and host immune cells in CD.

Methods

CD14-positive monocytes were isolated from peripheral blood mononuclear cells from healthy human volunteers and then differentiated in the presence of macrophage colony-stimulating factor (M-CSF) (referred to as M-macrophages, M-Mϕs) or M-CSF and interferon-γ (IFN-γ) (referred to as M-gamma macrophages, Mγ-Mϕs). Cytokine production by these in vitro differentiated macrophages in response to β-(1,3)-glucan was analyzed by flow cytometry. Expression of Dectin-1 was examined using flow cytometry, western blotting, and quantitative reverse transcription-polymerase chain reaction. Cytokine production by in vitro differentiated macrophages in response to β-(1,3)-glucan was measured in the presence of an anti-Dectin-1 receptor antagonist, anti-Syr, or an anti-Fas-1 antibody. Cytokine production by lamina propria mononuclear cells (LPMCs) derived from CD patients in response to β-(1,3)-glucan was also analyzed.

Results

Mγ-Mϕs produced a large amount of tumor necrosis factor-α (TNF-α) and interleukin-6 in response to β-(1,3)-glucan. Dectin-1 expression was significantly higher in Mγ-Mϕs than in M-Mϕs. The increase in TNF-α production by Mγ-Mϕs stimulated with glucan was reversed by blocking Dectin-1, Syr or Fas-1. LPMCs derived from CD patients stimulated with β-(1,3)-glucan produced significantly higher amount of TNF-α than LPMCs derived from UC patients.

Conclusions

These results suggest that commensal fungal microbiota may contribute to the pathogenesis of CD by inducing macrophages-derived pro-inflammatory cytokines.

Citations

Citations to this article as recorded by

Heat Shock Protein SSA1 Enriched in Hypoxic Secretome of Candida albicans Exerts an Immunomodulatory Effect via Regulating Macrophage Function
Wei Teng, Phawinee Subsomwong, Kouji Narita, Akio Nakane, Krisana Asano
Cells.2024; 13(2): 127. CrossRef
Antifungal immunity mediated by C-type lectin receptors may be a novel target in immunotherapy for urothelial bladder cancer
Tianhang Li, Tianyao Liu, Zihan Zhao, Yuchen Pan, Xinyan Xu, Yulin Zhang, Shoubin Zhan, Shengkai Zhou, Wenjie Zhu, Hongqian Guo, Rong Yang
Frontiers in Immunology.2022;[Epub] CrossRef
Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease
Katia Farias e Silva, Hayandra F Nanini, Cynthia Machado Cascabulho, Siane L B Rosas, Patricia T Santana, Antonio José de V Carneiro, Elias Anaissie, Marcio Nucci, Heitor Siffert Pereira de Souza
World Journal of Gastroenterology.2021; 27(9): 866. CrossRef
Effects of Medicinal Fungi-Derived β-Glucan on Tumor Progression
Vaclav Vetvicka, Tamara V. Teplyakova, Alexandra B. Shintyapina, Tatiana A. Korolenko
Journal of Fungi.2021; 7(4): 250. CrossRef
The Role of IL-17-Producing Cells in Cutaneous Fungal Infections
Yu Sawada, Ayako Setoyama, Yumiko Sakuragi, Natsuko Saito-Sasaki, Haruna Yoshioka, Motonobu Nakamura
International Journal of Molecular Sciences.2021; 22(11): 5794. CrossRef

9,848 View
121 Download
5 Web of Science
5 Crossref

Endoscopy

Difficult colonoscopy: air, carbon dioxide, or water insufflation?: Alisha Chaubal, Vikas Pandey, Ruchir Patel, Prateik Poddar, Aniruddha Phadke, Meghraj Ingle, Prabha Sawant; Intest Res 2018;16(2):299-305. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.299

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

This study aimed to compare tolerance to air, carbon dioxide, or water insufflation in patients with anticipated difficult colonoscopy (young, thin, obese individuals, and patients with prior abdominal surgery or irradiation).

Methods

Patients with body mass index (BMI) less than 18 kg/m² or more than 30 kg/m², or who had undergone previous abdominal or pelvic surgeries were randomized to air, carbon dioxide, or water insufflation during colonoscopy. The primary endpoint was cecal intubation with mild pain (less than 5 on visual analogue scale [VAS]), without use of sedation.

Results

The primary end point was achieved in 32.7%, 43.8%, and 84.9% of cases with air, carbon dioxide and water insufflation (P<0.001). The mean pain scores were 5.17, 4.72, and 3.93 on the VAS for air, carbon dioxide, and water insufflation (P<0.001). The cecal intubation rate or procedure time did not differ significantly between the 3 groups.

Conclusions

Water insufflation was superior to air or carbon dioxide for pain tolerance. This was seen in the subgroups with BMI <18 kg/m² and the post-surgical group, but not in the group with BMI >30 kg/m².

Citations

Citations to this article as recorded by

Retrograde colon imaging through colonic transendoscopic enteral tubing helps to confirm the cause of difficult colonoscopy: a case report
Xiaomeng Jiang, Runqing Wang, Haibo Sun, Faming Zhang
Therapeutic Advances in Gastrointestinal Endoscopy.2024;[Epub] CrossRef
Causes of intraprocedural discomfort in colonoscopy: a review and practical tips
Jabed F. Ahmed, Ara Darzi, Lakshmana Ayaru, Nisha Patel
Therapeutic Advances in Gastrointestinal Endoscopy.2024;[Epub] CrossRef
Research on driving force of capsule endoscope in fluid
Zhifan Teng, Jianhua Liu, Hongbo Sun, Quanyue Liu, Yujia Zhai, Qiuliang Wang
Archive of Applied Mechanics.2023; 93(12): 4387. CrossRef
Robot-assisted magnetic capsule endoscopy; navigating colorectal inclinations
Salman Mahmood, Sebastian Schostek, Marc O. Schurr, Jacob Bergsland, Ilangko Balasingham, Erik Fosse
Minimally Invasive Therapy & Allied Technologies.2022; 31(6): 930. CrossRef
Magnetic endoscopic imaging as a rational investment for specific colonoscopies: a systematic review and meta-analysis
Xiangzhou Tan, Weimin Yang, Doerte Wichmann, Changhao Huang, Benedikt Mothes, K.E. Grund, Zhikang Chen, Zihua Chen
Expert Review of Gastroenterology & Hepatology.2021; 15(4): 447. CrossRef
Screening colonoscopy: The present and the future
Chelsea V Hayman, Dinesh Vyas
World Journal of Gastroenterology.2021; 27(3): 233. CrossRef
Transparent cap‐assisted, water‐exchange colonoscopy in previous incomplete difficult colonoscopy patients: A retrospective study
Lien‐Fu Lin, Pi‐Teh Huang
Advances in Digestive Medicine.2020; 7(3): 118. CrossRef
Can water insufflation and carbon dioxide overcome the difficulties of colonoscope insertion?
Choong-Kyun Noh, Kee Myung Lee
Intestinal Research.2018; 16(2): 166. CrossRef

6,401 View
85 Download
8 Web of Science
8 Crossref

Endoscopy

Prospective analysis of factors associated with inadequate bowel preparation for colonoscopy in actual clinical practice: Dae Hyung Woo, Kyeong Ok Kim, Da Eun Jeong, Yoon Jeong Nam, Si Hyung Lee, Byung Ik Jang, Tae Nyeun Kim; Intest Res 2018;16(2):293-298. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.293

Abstract PDF PubReader ePub

Background/Aims

Inadequate bowel preparation can result in prolonged procedure time and increased missed lesion and complication rates. This prospective study aimed to evaluate bowel preparation quality and identify the predictive factors for inadequate bowel preparation in actual clinical practice.

Methods

We included 399 patients who underwent colonoscopy between June 2015 and July 2016. Using the Aronchick bowel preparation scale, we defined a score ≤2 as adequate preparation and a score >2 as inadequate preparation.

Results

Mean patient age was 58.38±12.97 years; 60.6% were male. Indications for colonoscopy included screening (69.7%) and surveillance after polyp removal (21.3%). A split-dose regimen was prescribed to 55.4% of patients. The inadequate bowel preparation rate was 28.1%. Overall, the median time between the last bowel preparation agent dose and start of colonoscopy was 5.0 hours (range, 1.5–16.0 hours); that of the adequate group was 5.0 hours (range, 1.5–16.0 hours); and that of the inadequate group was 5 hours (range, 2–23 hours). The mean bowel preparation scale score of the ascending colon (1.94±0.25) was significantly higher than that of other colon segments. On multivariate analysis, elderly age, history of cerebrovascular disease, history of gastrectomy or appendectomy, and total preparation solution uptake <2 L were the independent predictors of inadequate bowel preparation.

Conclusions

The inadequate bowel preparation rate was 28.1%. Risk factors included elderly age and history of cerebrovascular disease or abdominal surgery. Patients with these risk factors require special care and education.

Citations

Citations to this article as recorded by

Strategies to improve screening colonoscopy quality for the prevention of colorectal cancer
Joo Hye Song, Eun Ran Kim
The Korean Journal of Internal Medicine.2024; 39(4): 547. CrossRef
A study on the related influencing factors of the quality of bowel preparation and the compliance of middle-aged and elderly patients for colonoscopy
Shanshan Chen, Tingting Zhang, Saie Zhu, Yi Zhou
Current Medical Research and Opinion.2024; 40(9): 1545. CrossRef
Performance of Computer-Aided Detection and Quality of Bowel Preparation: A Comprehensive Analysis of Colonoscopy Outcomes
Dalton A. Norwood, Shyam Thakkar, Amanda Cartee, Fayez Sarkis, Tatiana Torres-Herman, Eleazar E. Montalvan-Sanchez, Kirk Russ, Patricia Ajayi-Fox, Anam Hameed, Ramzi Mulki, Sergio A. Sánchez-Luna, Douglas R. Morgan, Shajan Peter
Digestive Diseases and Sciences.2024;[Epub] CrossRef
Optimization of colonoscopy quality: Comprehensive review of the literature and future perspectives
Wen‐Feng Hsu, Han‐Mo Chiu
Digestive Endoscopy.2023; 35(7): 822. CrossRef
Risk Factors Associated with Painful Colonoscopy and Prolonged Cecal Intubation Time in Female Patients
Yasuhiko Hamada, Kyosuke Tanaka, Yohei Ikenoyama, Noriyuki Horiki, Junya Tsuboi, Reiko Yamada, Misaki Nakamura, Hayato Nakagawa
Journal of the Anus, Rectum and Colon.2023; 7(3): 168. CrossRef
The effect of educational compilation through video tutorials and visual AIDS on the quality of bowel preparation in patients undergoing colonoscopy
Jahanbakhsh Amirarsalani, Leyla Alilu, Masoumeh Hemmati-Maslakpak, Javad Rasouli
Acta Facultatis Medicae Naissensis.2023; 40(3): 307. CrossRef
A predictive model for early death in elderly colorectal cancer patients: a population-based study
Qi Wang, Kexin Shen, Bingyuan Fei, Hai Luo, Ruiqi Li, Zeming Wang, Mengqiang Wei, Zhongshi Xie
Frontiers in Oncology.2023;[Epub] CrossRef
Regression and Random Forest Machine Learning Have Limited Performance in Predicting Bowel Preparation in Veteran Population
Jacob E. Kurlander, Akbar K. Waljee, Stacy B. Menees, Rachel Lipson, Alex N. Kokaly, Andrew J. Read, Karmel S. Shehadeh, Amy Cohn, Sameer D. Saini
Digestive Diseases and Sciences.2022; 67(7): 2827. CrossRef
Comparison of 2 L Polyethylene Glycol Plus Ascorbic Acid and 4 L Polyethylene Glycol in Elderly Patients Aged 60–79: A Prospective Randomized Study
Sung Hoon Jung, Chul-Hyun Lim, Tae-Geun Gweon, Jinsu Kim, Jung Hwan Oh, Kyu-Tae Yoon, Jee Young An, Jeong‑Seon Ji, Hwang Choi
Digestive Diseases and Sciences.2022; 67(10): 4841. CrossRef
Quality indicators in colonoscopy: the chasm between ideal and reality
Su Bee Park, Jae Myung Cha
Clinical Endoscopy.2022; 55(3): 332. CrossRef
Efficacy, safety and tolerability of oral sulphate tablet for bowel preparation in patients with inflammatory bowel disease: A multicentre randomized controlled study
Kyeong Ok Kim, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Eun Soo Kim, Yun Jin Chung, Byung Ik Jang, Sung Kook Kim, Chang Heon Yang
Journal of Crohn's and Colitis.2022; 16(11): 1706. CrossRef
Comparison of Two Types of 1-L Polyethylene Glycol-ascorbic Acid as Colonoscopic Bowel Preparation: A Prospective Randomized Study
Suh Hyun Choi, Won Eui Yoon, Seung Hyuk Kim, Hee Jun Myung, Seo Hyun Kim, Soon Oh So, Se Hun Kim, Hyun Mi Lee, Yeoun Jung Oh, Jeong Seop Moon, Tae Yeong Park, You Sun Kim
The Korean Journal of Gastroenterology.2022; 80(2): 85. CrossRef
Comparative Effectiveness of Commercial Bowel Preparations in Ambulatory Patients Presenting for Screening or Surveillance Colonoscopy
Shashank Sarvepalli, Ari Garber, Carol A. Burke, Niyati Gupta, Mounir Ibrahim, John McMichael, Gareth Morris-Stiff, Amit Bhatt, John Vargo, Maged Rizk, Michael B. Rothberg
Digestive Diseases and Sciences.2021; 66(6): 2059. CrossRef
Quality Improvement of Bowel Preparation for Screening Colonoscopies: A Study of Hospital Team Resource Management in Taiwan
Chen-Shuan Chung, Chih-Ming Lin, Ming-Shu Chen
Quality Management in Health Care.2021; 30(2): 127. CrossRef
Postgastrectomy gastric cancer patients are at high risk for colorectal neoplasia: a case control study
Tae-Geun Gweon, Kyu-Tae Yoon, Chang Hyun Kim, Jin-Jo Kim
Intestinal Research.2021; 19(2): 239. CrossRef
How to Choose the Optimal Bowel Preparation Regimen for Colonoscopy
Ji Eun Na, Eun Ran Kim
The Ewha Medical Journal.2021; 44(4): 122. CrossRef
Factors related to Bowel Cleanliness of Colonoscopy Examinees
Yohan Lee, Haejung Lee
Korean Journal of Adult Nursing.2021; 33(6): 545. CrossRef
Comparison of bowel-cleansing efficacy of split-dose and same-day dose bowel preparation for afternoon colonoscopy in patients with gastrectomy: a prospective randomized study
Tae-Geun Gweon, Cheal Wung Huh, Jeong Seon Ji, Chang Hyun Kim, Jin-Jo Kim, Seung-Man Park
Surgical Endoscopy.2020; 34(10): 4413. CrossRef
Combination of bisacodyl suppository and 1 L polyethylene glycol plus ascorbic acid is a non‐inferior and comfortable regimen compared to 2 L polyethylene glycol plus ascorbic acid
Sun Hwa Kim, Eun Ran Kim, Kyunga Kim, Tae Jun Kim, Sung Noh Hong, Dong Kyung Chang, Young‐Ho Kim
Digestive Endoscopy.2020; 32(4): 600. CrossRef
Efficacy and Patient Tolerability Profiles of Probiotic Solution with Bisacodyl Versus Conventional Cleansing Solution for Bowel Preparation: A Prospective, Randomized, Controlled Trial
Youn I Choi, Jong-Joon Lee, Jun-Won Chung, Kyoung Oh Kim, Yoon Jae Kim, Jung Ho Kim, Dong Kyun Park, Kwang An Kwon
Journal of Clinical Medicine.2020; 9(10): 3286. CrossRef
Educational virtual reality videos in improving bowel preparation quality and satisfaction of outpatients undergoing colonoscopy: protocol of a randomised controlled trial
Yi Zhao, Feng Xie, Xiaoyin Bai, Aiming Yang, Dong Wu
BMJ Open.2019; 9(8): e029483. CrossRef
Impact of diet restriction on bowel preparation for colonoscopy
Seung-Joo Nam, Young Jin Kim, Bora Keum, Jae Min Lee, Seung Han Kim, Hyuk Soon Choi, Eun Sun Kim, Yeon Seok Seo, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Soon Ho Um, Chang Duck Kim
Medicine.2018; 97(41): e12645. CrossRef

5,504 View
90 Download
24 Web of Science
22 Crossref

Miscellaneous

A simple phenotypic classification for celiac disease: Ajit Sood, Vandana Midha, Govind Makharia, B. K. Thelma, Shivalingappa S Halli, Varun Mehta, Ramit Mahajan, Vikram Narang, Kriti Sood, Kirandeep Kaur; Intest Res 2018;16(2):288-292. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.288

Abstract PDF PubReader ePub

Background/Aims

Celiac disease is a global health problem. The presentation of celiac disease has unfolded over years and it is now known that it can manifest at different ages, has varied presentations, and is prone to develop complications, if not managed properly. Although the Oslo definitions provide consensus on the various terminologies used in literature, there is no phenotypic classification providing a composite diagnosis for the disease.

Methods

Various variables identified for phenotypic classification included age at diagnosis, age at onset of symptoms, clinical presentation, family history and complications. These were applied to the existing registry of 1,664 patients at Dayanand Medical College and Hospital, Ludhiana, India. In addition, age was evaluated as below 15 and below 18 years. Cross tabulations were used for the verification of the classification using the existing data. Expert opinion was sought from both international and national experts of varying fields.

Results

After empirical verification, age at diagnosis was considered appropriate in between A1 (<18) and A2 (≥18). The disease presentation has been classified into 3 types–P1 (classical), P2 (non-classical) and P3 (asymptomatic). Complications were considered as absent (C0) or present (C1). A single phenotypic classification based on these 3 characteristics, namely age at the diagnosis, clinical presentation, and intestinal complications (APC classification) was derived.

Conclusions

APC classification (age at diagnosis, presentation, complications) is a simple disease explanatory classification for patients with celiac disease aimed at providing a composite diagnosis.

Citations

Citations to this article as recorded by

Clinicopathologic Analysis of Malabsorption Syndrome in a Tertiary Care Center in South India
Nidhya Ganesan, S. Shrinnivi, R. Shivani, R. K. Kartikayan
Medical Journal of Dr. D.Y. Patil Vidyapeeth.2024; 17(3): 616. CrossRef
Prevalence of haplotype DQ2/DQ8 and celiac disease in children with type 1 diabetes
Agnieszka Zubkiewicz-Kucharska, Tatiana Jamer, Joanna Chrzanowska, Katarzyna Akutko, Tomasz Pytrus, Andrzej Stawarski, Anna Noczyńska
Diabetology & Metabolic Syndrome.2022;[Epub] CrossRef
Celiac crisis, a rare occurrence in adult celiac disease: A systematic review
Daniel Vasile Balaban, Alina Dima, Ciprian Jurcut, Alina Popp, Mariana Jinga
World Journal of Clinical Cases.2019; 7(3): 311. CrossRef
The spectrum of clinical and subclinical endocrinopathies in treatment-naïve patients with celiac disease
Vipin Gupta, Alka Singh, Rajesh Khadgawat, Ashish Agarwal, Asif Iqbal, Wajiha Mehtab, P.K. Chaturvedi, Vineet Ahuja, Govind K. Makharia
Indian Journal of Gastroenterology.2019; 38(6): 518. CrossRef

5,937 View
106 Download
3 Web of Science
4 Crossref

IBD

Intraoperative inspection alone is a reliable guide to the choice of surgical procedure for enteroenteric fistulas in Crohn's disease: Zhen Guo, Xingchen Cai, Ruiqing Liu, Jianfeng Gong, Yi Li, Lei Cao, Weiming Zhu; Intest Res 2018;16(2):282-287. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.282

Abstract PDF PubReader ePub

Background/Aims

Resection of the diseased segment and suture of the victim segment is recommended for enteroenteric fistula in Crohn's disease (CD). The main difficulty in this procedure remains reliable diagnosis of the victim segment, especially for fistulas found intraoperatively and inaccessible on endoscopic examination. We aimed to explore whether intraoperative inspection alone is reliable.

Methods

Patients undergoing conservative surgery between 2011 and 2016 for enteroenteric fistulas complicating CD were identified from a prospectively maintained database. Patients were divided according to whether the victim segment was evaluated by preoperative endoscopy + intraoperative inspection (PI group) or by intraoperative inspection alone (I group). Outcomes were compared.

Results

Of 65 patients eligible for the study, 37 were in in the PI group and 28 were in the I group. The baseline characteristics were similar between the groups, except for the rate of emergency surgery (0/37 in PI group vs. 5/28 in I group, P=0.012). Fistulas involved more small intestines (4/37 in PI group vs. 15/28 in I group, P<0.001) and fewer sigmoid colons (17/37 in PI group vs. 4/28 in I group, P=0.008) in I group due to accessibility with endoscopy. No difference was found in postoperative complications, stoma rates, postoperative recurrence, or disease at the repair site between the 2 groups (P>0.05).

Conclusions

For fistulas found intraoperatively and inaccessible on endoscopic examination, intraoperative inspection was a reliable guide when choosing between en bloc resection and a conservative procedure.

Citations

Citations to this article as recorded by

Diagnosis and Classification of Fistula from Inflammatory Bowel Disease and Inflammatory Bowel Disease-Related Surgery
Sarah Householder, Joseph A. Picoraro
Gastrointestinal Endoscopy Clinics of North America.2022; 32(4): 631. CrossRef

5,398 View
51 Download
1 Crossref

IBD

Evaluation of the drug-induced lymphocyte stimulation test for diagnosing mesalazine allergy: Daisuke Saito, Mari Hayashida, Taro Sato, Shintaro Minowa, Osamu Ikezaki, Tatsuya Mitsui, Miki Miura, Akihito Sakuraba, Tadakazu Hisamatsu; Intest Res 2018;16(2):273-281. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.273

Abstract PDF PubReader ePub

Background/Aims

Mesalazine is an effective drug for treating ulcerative colitis (UC), but causes allergic symptoms in a few cases. Therefore, the objective of this study was to evaluate the usefulness of the drug-induced lymphocyte stimulation test (DLST) for the diagnosis of mesalazine allergy.

Methods

Patients with UC treated with mesalazine with or without a history of associated adverse events (AEs) were enrolled at Kyorin University Hospital from July 2016 to April 2017.

Results

The DLST was performed in 104 patients with UC, of which 24 had a history of AEs due to mesalazine treatment. The control value of DLST was 337.4±296.3 counts per minute (cpm) in the AE⁺ group and 408.0±371.9 cpm in the AE⁻ group. The measured value of DLST was 578.8±424.7 cpm in the AE⁺ group and 476.5±471.8 cpm in the AE⁻ group. The stimulation index (SI) was 243.9%±291.1% in the AE⁺ group and 119.8%±53.0% in the AE⁻ group. The SI value and DLST positivity were significantly higher in the AE⁺ group than in the AE⁻ group (P=0.030 and P=0.029, respectively). The test sensitivity and specificity were 0.240 and 0.805, respectively, and the false-positive and false-negative rate was 0.195 and 0.760, respectively.

Conclusions

The DLST for mesalazine showed low sensitivity and high specificity, suggesting that it may be useful for the definitive diagnosis of allergy to mesalazine.

Citations

Citations to this article as recorded by

Drug-induced Interstitial Nephritis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid
Daichi Hayashi, Tsutomu Nishida, Naoto Osugi, Yasuo Kusunoki, Satoru Okabe, Yoshifumi Fujii, Dai Nakamatsu, Kengo Matsumoto, Masashi Yamamoto, Koji Fukui
Internal Medicine.2024; 63(8): 1081. CrossRef
Hemodialysis patients with allergic reactions to dialysate whose symptoms improved without dialysate change：Two case reports
Hisato Shima, Yoko Nishiuchi, Yoshio Fukata, Takuya Okamoto, Manabu Tashiro, Tomoko Inoue, Hiroyasu Bando, Hiroyuki Azuma, Naohito Iwasaka, Takuji Ohara, Toshio Doi, Kazuyoshi Okada, Jun Minakuchi
Nihon Toseki Igakkai Zasshi.2024; 57(1): 23. CrossRef
Allergic clinical symptoms and distribution of stimulation index of drug lymphocyte stimulation test for local anesthetics
Yukiko Baba, Yu Sato, Ken Takahashi, Takaya Ito, Ryo Wakita, Shigeru Maeda
Oral and Maxillofacial Surgery.2024;[Epub] CrossRef
Lymphocyte stimulation test for diagnosing hen’s egg yolk–induced enterocolitis syndrome
Naoki Kajita, Go Kusakawa, Hiroki Seto, Keiko Hirao, Shoko Yokoyama, Emi Morikawa, Kumiko Morita, Masami Narita, Koichi Yoshida
Journal of Allergy and Clinical Immunology: Global.2023; 2(4): 100138. CrossRef
Risk factors for intolerance of oral 5‐aminosalicylic acid preparations in pediatric ulcerative colitis
Naoki Abe, Naomi Iwata, Ryuhei Yasuoka, Daisuke Nishida, Asami Oohara, Haruna Nakaseko, Shiro Sugiura, Shinji Kawabe
Pediatrics International.2023;[Epub] CrossRef
Pulmonary Manifestations of Inflammatory Bowel Disease and Treatment Strategies
Subha Ghosh, Himanshu Deshwal, Rebecca Haraf, Shine Raju, Mnahi Bin Saeedan, Pralay Sarkar, Thomas Gildea, Carol F. Farver, Atul C. Mehta
CHEST Pulmonary.2023; 1(3): 100018. CrossRef
Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis
Yohei Mikami, Junya Tsunoda, Shohei Suzuki, Ichiro Mizushima, Hiroki Kiyohara, Takanori Kanai
Digestion.2023; 104(1): 58. CrossRef
The Forefront of Drug Therapy for Ulcerative Colitis
Tadakazu Hisamatsu, Daisuke Saito, Minoru Matsuura
Nippon Daicho Komonbyo Gakkai Zasshi.2023; 76(10): 580. CrossRef
Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease
Kaoru Suzuki, Yoichi Kakuta, Takeo Naito, Tetsuya Takagawa, Hiroyuki Hanai, Hiroshi Araki, Yu Sasaki, Hirotake Sakuraba, Makoto Sasaki, Tadakazu Hisamatsu, Satoshi Motoya, Takayuki Matsumoto, Motoyuki Onodera, Yoh Ishiguro, Hiroshi Nakase, Akira Andoh, Sa
Inflammatory Bowel Diseases.2022; 28(1): 21. CrossRef
A complicated case of Serratia marcescens catheter-related bloodstream infection misdiagnosed as hypersensitivity reactions to bicarbonate dialysate containing acetate
Hisato Shima, Takuya Okamoto, Tomoko Inoue, Manabu Tashiro, Yusaku Tanaka, Norimichi Takamatsu, Seiichiro Wariishi, Kazuhiko Kawahara, Kazuyoshi Okada, Jun Minakuchi
CEN Case Reports.2022; 11(1): 55. CrossRef
Cyanamide-induced oral lichenoid drug reaction: Case report and literature review
Yurie Akiyama, Yusuke Oomura, Masahiro Okamura, Chiho Hiraga-Kondo, Taiki Suzuki, Kazumichi Sato, Shinichi Takahashi, Takeshi Nomura
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology.2022; 34(2): 209. CrossRef
5‐Aminosalicylic acid‐induced pericarditis in pediatric Crohn’s disease
Yuki Toguchi, Kahoru Fukuoka‐Araki, Kei Matayoshi, Saori Kinjo, Toshifumi Yodoshi
Pediatrics International.2022;[Epub] CrossRef
Hematochezia Due to Panitumumab-induced Colitis with Vitamin K Deficiency
Hotaka Tamura, Koji Nakashima, Naomi Uchiyama, Souichiro Ogawa, Hiroshi Hatada, Naoki Yoshida, Keisuke Uchida, Yoshinori Ozono, Hiroyuki Tanaka, Koji Yamamto, Hiroshi Kawakami
Internal Medicine.2022; 61(10): 1503. CrossRef
A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis
Mimari Kanazawa, Keiichi Tominaga, Akira Kanamori, Takanao Tanaka, Satoshi Masuyama, Shoko Watanabe, Keiichiro Abe, Akira Yamamiya, Kenichi Goda, Atsushi Irisawa
Medicina.2022; 58(2): 276. CrossRef
A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease
Kevin Cesa, Catherine Cunningham, Tyler Harris, Whitney Sunseri
Cureus.2022;[Epub] CrossRef
Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis
Yuki Minagawa, Kazuhiko Uchiyama, Tomohisa Takagi, Katsura Mizushima, Kohei Asaeda, Mariko Kajiwara-Kubota, Saori Kashiwagi, Yuma Hotta, Makoto Tanaka, Ken Inoue, Osamu Dohi, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Katada, Kazuhiro Kamada, Takeshi Ishi
Journal of Clinical Biochemistry and Nutrition.2022; 71(3): 249. CrossRef
Multicenter survey on mesalamine intolerance in patients with ulcerative colitis
Sakiko Hiraoka, Akiko Fujiwara, Tatsuya Toyokawa, Reiji Higashi, Yuki Moritou, Shinjiro Takagi, Kazuhiro Matsueda, Seiyuu Suzuki, Jiro Miyaike, Toshihiro Inokuchi, Masahiro Takahara, Jun Kato, Hiroyuki Okada
Journal of Gastroenterology and Hepatology.2021; 36(1): 137. CrossRef
Maternal mesalazine-induced neonatal gastrointestinal bleeding
Kohichiroh Nii, Kaoru Okazaki, Hitoshi Okada, Toru Kuboi
BMJ Case Reports.2021; 14(4): e238743. CrossRef
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu I
Journal of Gastroenterology.2021; 56(6): 489. CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef
Hypersensitivity reactions to bicarbonate dialysate containing acetate: a case report with literature review
Yoko Nishiuchi, Hisato Shima, Yoshio Fukata, Tomohiro Tao, Takuya Okamoto, Norimichi Takamatsu, Kazuyoshi Okada, Jun Minakuchi
CEN Case Reports.2020; 9(3): 243. CrossRef
Anaphylaxis to three humanized antibodies for severe asthma: a case study
Koichi Jingo, Norihiro Harada, Toshihiko Nishioki, Masahiro Torasawa, Tomoko Yamada, Tetsuhiko Asao, Haruhi Takagi, Tomohito Takeshige, Jun Ito, Kazuhisa Takahashi
Allergy, Asthma & Clinical Immunology.2020;[Epub] CrossRef
Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report
Yoshinori Arai, Maiko Ogawa, Fumitsugu Yamane, Natsuki Sumiyoshi, Rikako Arimoto, Yoshitaka Ando, Daisuke Endo, Tatsuya Nakada, Ichiro Sugawara, Hiroshi Yokoyama, Keiko Shimoyama, Hiroko Inomata, Yosuke Kawahara, Masayuki Kato, Seiji Arihiro, Atsushi Hoka
Clinical Journal of Gastroenterology.2020; 13(6): 1200. CrossRef
Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
Satohiro Matsumoto, Hirosato Mashima
Scientific Reports.2020;[Epub] CrossRef
Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis
Rumiko Tsuboi, Satohiro Matsumoto, Hiroyuki Miyatani, Hirosato Mashima
Internal Medicine.2019; 58(5): 649. CrossRef
Allergic reactions to small-molecule drugs: Will we move from reaction to prediction?
Mark F Bonfiglio, David M Weinstein
American Journal of Health-System Pharmacy.2019; 76(9): 574. CrossRef

7,006 View
231 Download
22 Web of Science
26 Crossref

IBD

Is Clostridium difficile infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea: Dae Bum Kim, Kang-Moon Lee, Sang Hyoung Park, You Sun Kim, Eun Soo Kim, Jun Lee, Sung-Ae Jung, Geom Seog Seo, Ji Min Lee; Intest Res 2018;16(2):267-272. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.267

Abstract PDF PubReader ePub

Background/Aims

Clostridium difficile infection (CDI) has been reported to be a cause of flare-ups in patients with ulcerative colitis (UC). We evaluated the prevalence and clinical outcomes of CDI in patients with UC hospitalized for flare-ups.

Methods

This was a prospective, multicenter study including 7 academic teaching hospitals in Korea. All consecutive patients with UC admitted for disease flare-up were enrolled. We detected the presence of CDI by using enzyme immunoassay, real-time polymerase chain reaction (RT-PCR) for toxin genes, and sigmoidoscopy.

Results

Eighty-one consecutive patients with UC were enrolled from January 2014 to December 2015. Among 81 patients, 8 (9.9%) were diagnosed with CDI. Most of the cases were identified by RT-PCR. Enzyme immunoassay was positive in 3 of 8 patients, and only 1 had typical endoscopic findings of pseudomembranous colitis. There were no differences in demographic data, length of hospital stay, or colectomy rate between patients with and without CDI.

Conclusions

CDI was not a rare cause of flare-up in patients with UC in Korea. However, CDI did not appear to affect the course of UC flare-up in Korean patients. RT-PCR was sensitive in detecting CDI and can be considered a diagnostic tool in patients with UC flare-up.

Citations

Citations to this article as recorded by

Low prevalence of Clostridioides difficile infection in acute severe ulcerative colitis: A retrospective cohort study from northern India
Sandeep Mundhra, David Thomas, Saransh Jain, Pabitra Sahu, Sudheer Vuyyuru, Peeyush Kumar, Bhaskar Kante, Rajesh Panwar, Peush Sahni, Rama Chaudhry, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Indian Journal of Gastroenterology.2023; 42(3): 411. CrossRef
The Prevalence and Risk Factors of Clostridioides difficile Infection in Inflammatory Bowel Disease: 10-Year South Korean Experience Based on the National Database
Eun Mi Song, Arum Choi, Sukil Kim, Sung Hoon Jung
Journal of Korean Medical Science.2023;[Epub] CrossRef
Clostridioides Infection in Patients with Inflammatory Bowel Disease
Mi Rae Lee, Eun Soo Kim
The Korean Journal of Gastroenterology.2022; 80(2): 66. CrossRef
Clostridium difficile in ulcerative colitis; a retrospective study
O. V. Knyazev, A. V. Kagramanova, M. E. Chernova, I. A. Koroleva, A. I. Parfenov
Almanac of Clinical Medicine.2018; 46(5): 474. CrossRef

5,889 View
89 Download
4 Web of Science
4 Crossref

IBD

Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study: Haruhiko Ogata, Tadashi Yokoyama, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi; Intest Res 2018;16(2):255-266. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.255

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

This study compared the efficacy of multimatrix mesalazine 2.4 g/day and 4.8 g/day with controlled-release mesalazine 2.25 g/day.

Methods

In this multicenter, randomized, double-blind study, 251 patients with mildly to moderately active ulcerative colitis received multimatrix mesalazine 2.4 g/day once daily (Multimatrix-2.4), 4.8 g/day once daily (Multimatrix-4.8), or controlled-release (time-dependent) mesalazine 2.25 g/day 3 times daily (Time-2.25) for 8 weeks. The primary efficacy endpoint was the change in the ulcerative colitis-disease activity index (UC-DAI) score.

Results

The mean change in the UC-DAI score and standard deviation in the per protocol set was −1.9±2.5 for Multimatrix-2.4 and −2.4±2.8 for Time-2.25. The difference between Multimatrix-2.4 and Time-2.25 was 0.3 (two-sided 95% confidence interval [CI], −0.5 to 1.1), thus non-inferiority was not demonstrated based on the pre-defined non-inferiority margin (1.0). In the full analysis set, the difference between Multimatrix-4.8 and Time-2.25 was −1.2 (two-sided 95% CI, −2.0 to −0.5), and the mean change in UC-DAI score in the FAS was −3.3 (two-sided 95% CI, −3.9 to −2.8) for Multimatrix-4.8 and −1.9 (two-sided 95% CI, −2.5 to −1.3) for Multimatrix-2.4, indicating that Multimatrix-4.8 was more effective than Time-2.25 and Multimatrix-2.4. There was no difference among the treatment groups in terms of safety.

Conclusions

This study showed that the efficacy of multimatrix mesalazine 2.4 g/day was comparable to controlled release mesalazine 2.25 g/day, although non-inferiority was not demonstrated. Importantly, this was the first study to indicate that multimatrix mesalazine 4.8 g/day was more effective than 2.4g/day with no associated safety concerns.

Citations

Citations to this article as recorded by

The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment
Sara Hone Lopez, Mathilde Jalving, Rudolf S.N. Fehrmann, Wouter B. Nagengast, Elisabeth G.E. de Vries, Jacco J. de Haan
Cancer Treatment Reviews.2022; 107: 102406. CrossRef
Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S‐methyltransferase inhibition
Hiromu Morikubo, Taku Kobayashi, Ryo Ozaki, Shinji Okabayashi, Satoshi Kuronuma, Osamu Takeuchi, Tenyo Shiba, Hiroki Kiyohara, Mao Matsubayashi, Shintaro Sagami, Masaru Nakano, Osamu Ikezaki, Tadakazu Hisamatsu, Yoichi Tanaka, Toshifumi Hibi
Journal of Gastroenterology and Hepatology.2021; 36(8): 2116. CrossRef
Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis
Brigida Barberio, Jonathan P Segal, M Nabil Quraishi, Christopher J Black, Edoardo V Savarino, Alexander C Ford
Journal of Crohn's and Colitis.2021; 15(7): 1184. CrossRef
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu I
Journal of Gastroenterology.2021; 56(6): 489. CrossRef
Outcomes of a drug shortage requiring switching in patients with ulcerative colitis
Daniel R van Langenberg, Richard Kai-Yuan Cheng, Mayur Garg
World Journal of Gastrointestinal Pathophysiology.2020; 11(2): 32. CrossRef
Comparative assessment of budesonide‐MMX and mesalamine in active, mild‐to‐moderate ulcerative colitis: A systematic review and network meta‐analysis
Stefanos Bonovas, Georgios K. Nikolopoulos, Daniele Piovani, Marien González‐Lorenzo, Katerina Pantavou, Theodore Lytras, Laurent Peyrin‐Biroulet, Silvio Danese
British Journal of Clinical Pharmacology.2019; 85(10): 2244. CrossRef
Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents
Eriko Yasutomi, Sakiko Hiraoka, Shumpei Yamamoto, Shohei Oka, Mami Hirai, Yasushi Yamasaki, Toshihiro Inokuchi, Hideaki Kinugasa, Masahiro Takahara, Keita Harada, Jun Kato, Hiroyuki Okada
Journal of Clinical Medicine.2019; 8(12): 2109. CrossRef
Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
Seong Ran Jeon
Intestinal Research.2018; 16(2): 163. CrossRef

5,860 View
168 Download
7 Web of Science
8 Crossref

First
Prev
Page of 17
Next
Last

Original article